Page last updated: 2024-11-04

desipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Desipramine is a tricyclic antidepressant (TCA) medication used to treat major depressive disorder. It works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine and serotonin. Desipramine was first synthesized in the 1950s and has been used to treat depression for over 60 years. It is a potent inhibitor of the neuronal uptake of norepinephrine and serotonin. The compound is generally well-tolerated, but side effects can include dry mouth, blurred vision, constipation, drowsiness, and weight gain. Desipramine is still studied today to better understand its mechanism of action and to develop new treatments for depression and other mental health conditions.'

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2995
CHEMBL ID72
CHEBI ID47781
SCHEMBL ID34384
MeSH IDM0006074

Synonyms (137)

Synonym
demethylimipramine
DMI ,
AC-15977
bdbm35229
treyzafagit
gtpl2399
pertrofane
KBIO1_000190
DIVK1C_000190
n-(3-methylaminopropyl)iminobibenzyl
desmethylimipramine
sertofran
monodemethylimipramine
norpramine
5-(gamma-methylaminopropyl)iminodibenzyl
10, 11-dihydro-n-methyl-5h-dibez[b,f]azepine-5-propanamine
dmi 50475
norimipramine
ccris 7091
brn 1432747
desipramine [inn:ban]
desipramine (d4)
methylaminopropyliminodibenzyl
einecs 200-040-0
desipraminum [inn-latin]
desipramina [inn-spanish]
desimipramine
imipramine, demethyl-
5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-
hsdb 3052
dimethylimipramine
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n-methyl-
10,11-dihydro-5-(3-methylaminopropyl)-5h-dibenz(b,f)azepine
dezipramine
dmi (pharmaceutical)
SPECTRUM_000441
cas-58-28-6
NCGC00015340-02
NCGC00015340-01
lopac-d-3900
BSPBIO_002137
LOPAC0_000358
PRESTWICK3_000343
BPBIO1_000447
PRESTWICK2_000343
BSPBIO_000405
5h-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-n-methyl-
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n-methyl-propan-1-amine
(3-(10h,11h-dibenzo[b,f]azepin-5-yl)propyl)methylamine
AB00053450
C06943
50-47-5
desipramine
DB01151
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n-methylpropan-1-amine
desipramin
desipramina
CHEBI:47781 ,
desipraminum
KBIO2_006057
KBIOSS_000921
KBIOGR_000928
KBIO3_001357
KBIO2_000921
KBIO2_003489
NINDS_000190
SPECTRUM4_000314
SPECTRUM3_000379
SPBIO_000042
PRESTWICK0_000343
PRESTWICK1_000343
SPECTRUM2_000091
SPBIO_002326
IDI1_000190
SPECTRUM5_000833
NCGC00024375-04
NCGC00015340-03
NCGC00015340-10
L001089
CHEMBL72 ,
n-desmethylimipramine
desipramine (inn)
D07791
FT-0666024
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n-methylpropan-1-amine
STK735144
AKOS001681456
CCG-118231
NCGC00015340-09
NCGC00015340-11
NCGC00015340-04
NCGC00015340-07
NCGC00015340-06
NCGC00015340-05
NCGC00015340-08
desimpramine
unii-tg537d343b
tg537d343b ,
NCGC00015340-13
desipramine [vandf]
desipramine [mi]
desipramine [hsdb]
10,11-dihydro-5-(3-(methylamino)propyl)-5h-dibenz(b,f)azepine
imipramine hydrochloride impurity a [ep impurity]
desipramine [inn]
desipramine [who-dd]
SCHEMBL34384
5-(3-methylaminopropyl)-10,11-dihydro-5h-dibenzo[b,f]azepine
5h-dibenzo[b, f]azepine, n-(3-methylaminopropyl)-, 10,11-dihydro
5h-dibenz[b,f]azepine, 10,11-dihydro-5-[3-(methylamino)propyl]-
pertofrane (salt/mix)
pertofran (salt/mix)
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n-methyl-1-propanamine #
HMS3430H03
AB00053450_14
DTXSID6022896 ,
(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)(methyl)amine
imipramine-m nor
SBI-0050346.P004
desipramine;norpramin
Q423288
BRD-K60762818-003-15-3
n-[3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)propyl]-n-methylamine
SDCCGSBI-0050346.P005
NCGC00015340-22
HMS3742I19
desmethylimipramine;imipramine,demethyl-;methylaminopropyliminodibenzyl
4-(2h-tetrazol-5-yl)phenylboronicacid
EN300-18293453
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine
HY-B1272A
CS-8193
dtxcid902896
n06aa01
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n-methylpropan-1-amine
desipraminum (inn-latin)
desipramina (inn-spanish)

Research Excerpts

Overview

Desipramine is a secondary tricyclic amine, which is primarily metabolized by cytochrome 2D6. It is used to treat major depressive disorder, but also other pathologies such as neuropathic pain or Attention Deficit/hyperactivity disorder.

ExcerptReferenceRelevance
"Desipramine is a tricyclic antidepressant with immune-modulatory activity, whose effects on ligature-induced periodontitis are yet to be investigated. "( Protective effects of desipramine on alveolar bone in experimental periodontitis.
Anbinder, AL; Branco-de-Almeida, LS; Castro, ML; Cortelli, SC; Franco, GCN; Galvão-Moreira, LV; Kawai, T; Rosalen, PL; Vieira, MS, 2020
)
2.32
"Desipramine is a secondary tricyclic amine, which is primarily metabolized by cytochrome 2D6. "( Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study.
Lukacova, V; Samant, TS; Schmidt, S, 2017
)
2.1
"Desipramine is a typical tricyclic antidepressant, and can provide neuroprotection and counteract depression-like behaviors."( Desipramine rescues age-related phenotypes in depression-like rats induced by chronic mild stress.
Chen, Y; Fu, Z; Huang, L; Ma, L; Shen, Q; Wang, Q; Wu, T; Xie, X, 2017
)
2.62
"Desipramine is a representative of tricyclic-antidepressant agents."( Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells.
Bian, F; Jin, S; Mao, X; Yang, X; Yao, W; Zhang, Y; Zhen, H,
)
1.17
"Desipramine is a potential useful treatment for patients with OAB. "( Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy.
Bagadiya, N; Hillelsohn, JH; Kashan, M; Rais-Bahrami, S; Weiss, GH, 2014
)
2.3
"Desipramine is a tricyclic antidepressant with a negative side effect of dry mouth. "( Desipramine inhibits salivary Ca(2+) signaling and aquaporin translocation.
Choi, LM; Choi, S; Choi, SY; Chung, G; Kim, JH; Lee, G; Lee, J; Lee, K; Park, K, 2015
)
3.3
"Desipramine (DMI) is an antidepressant which is used to treat major depressive disorder, but also other pathologies such as neuropathic pain or attention-deficit/hyperactivity disorder."( Desipramine targets astrocytes to attenuate synaptic plasticity via modulation of the ephrinA3/EphA4 signalling.
Di Benedetto, B; Eder, M; Mattusch, C; Rammes, G; Rupprecht, R; Tanasic, S; Wagner, EM, 2016
)
2.6
"Desipramine (DMI) is a widely used tricyclic antidepressant, and it is the major metabolite of imipramine (IMI) and lofepramine (LMI); IMI and LMI are two of the most commonly used tricyclic antidepressants. "( UV-photodegradation of desipramine: Impact of concentration, pH and temperature on formation of products including their biodegradability and toxicity.
Khaleel, NDH; Kümmerer, K; Mahmoud, WMM; Olsson, O, 2016
)
2.19
"Desipramine (DMI) is a blocker of neuronal norepinephrine (NE) uptake transporter. "( Desipramine increases cardiac parasympathetic activity via α
Akiyama, T; Fukumitsu, M; Kamiya, A; Kawada, T; Shimizu, S; Sugimachi, M, 2017
)
3.34
"Desipramine (DMI) is a tricyclic antidepressant that alters male sexual function. "( DMI-induced sexual effects in male rats: analysis of DMI's acute and chronic actions on copulatory behavior and on the genital motor pattern of ejaculation.
Carro-Juárez, M; Hueletl-Soto, ME; Rodríguez-Manzo, G, 2010
)
1.8
"Desipramine is a tricyclic antidepressant for psychiatric disorders that can induce QT prolongation, which may lead to torsades de pointes. "( Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
Hong, HK; Jo, SH; Lee, BH; Park, MH, 2010
)
2.03
"Desipramine (DMI) is an antidepressant classically characterized as an inhibitor of norepinephrine reuptake."( The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo.
Chen, Y; Cottingham, C; Jiao, K; Wang, Q, 2011
)
1.42
"Desipramine (DP) is a tricyclic antidepressant used for treating depression and numerous other psychiatric disorders. "( Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells.
Chan, KH; Chang, YL; Chen, SJ; Chou, YP; Hsu, WM; Huang, YY; Peng, CH; Wang, HJ; Wu, CC; Yang, YP, 2007
)
3.23
"Desipramine, which is a tricyclic antidepressant, inhibited PKC activity in concentrations starting from 0.1 mmol/L in rat brain and its inhibitory effect on PKC activity did not involve competitive inhibition with calcium."( Effect of the tricyclic antidepressant desipramine on protein kinase C in rat brain and rabbit platelets in vitro.
Morishita, S; Watanabe, S, 1997
)
1.29
"1. Desipramine (DMI) is a tricyclic antidepressant which reduces the immobility in rats forced to swim; however, it is unknown whether estral cycle phases impinge on DMI actions on immobility in daily swimming tests during several weeks. "( Desipramine restricts estral cycle oscillations in swimming.
Contreras, CM; Martínez-Mota, L; Saavedra, M, 1998
)
2.36
"Desipramine is a tricyclic antidepressant with demonstrated efficacy for some children with attention deficit hyperactivity disorder (ADHD). "( Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder.
Chandler, M; Gualtieri, CT; Keenan, PA, 1991
)
1.99
"Desipramine (DMI) is an important antidepressant drug and a lysosomotropic substance. "( Subcellular distribution of the antidepressant drug desipramine in cultured human fibroblasts after chronic administration. Drug-effect on the subcellular distribution of accumulated phospholipids.
Burkart, T; Honegger, UE; Stoffel, P; Wiesmann, UN, 1987
)
1.97

Effects

Desipramine has a low incidence of anticholinergic side effects, causes little orthostatic hypotension, and has a quinidine-like effect on cardiac arrhythmias.

Desipramine has a low incidence of anticholinergic side effects, causes little orthostatic hypotension, and has a quinidine-like effect on cardiac arrhythmias. It has been shown in one small study to have efficacy equal to amitriptyline.

ExcerptReferenceRelevance
"Desipramine has a low incidence of anticholinergic side effects, causes little orthostatic hypotension, and has a quinidine-like effect on cardiac arrhythmias."( Use of desipramine in the medically ill.
Cavanaugh, SV, 1984
)
1.44
"Desipramine has an antiarrhythmic effect in patients with chronic ventricular ectopy, but its clinical utility is limited by adverse effects."( Antiarrhythmic efficacy of desipramine.
Bressler, R; Fenster, PE; Kipps, J, 1989
)
1.3
"Desipramine (DMI) has been reported to induce glucocorticoid receptor-mediated signal transduction in recent studies. "( Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells.
Hanausek, M; Kinjo, T; Kowalczyk, M; Kowalczyk, P; Slaga, TJ; Walaszek, Z, 2010
)
2.19
"Desipramine has a low incidence of anticholinergic side effects, causes little orthostatic hypotension, and has a quinidine-like effect on cardiac arrhythmias."( Use of desipramine in the medically ill.
Cavanaugh, SV, 1984
)
1.44
"Desipramine has been shown in one small study to have efficacy equal to amitriptyline."( Tricyclic antidepressant use in diabetic neuropathy.
Joss, JD, 1999
)
1.02
"Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressants."( Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial.
Dubner, R; Gracely, RH; Kishore-Kumar, R; Max, MB; Meister, B; Schafer, SC; Smoller, B, 1991
)
1.38
"Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressant agents, but its pain-relieving potential has received little study. "( Desipramine relieves postherpetic neuralgia.
Dubner, R; Gaughan, AM; Gracely, RH; Kishore-Kumar, R; Max, MB; Schafer, SC; Smoller, B, 1990
)
3.16
"Desipramine, which has been used clinically for the treatment of withdrawal of cocaine, also depressed neuronal activity in the caudate nucleus."( Effects of microiontophoretic application of cocaine, alone and with receptor antagonists, upon the neurons of the medial prefrontal cortex, nucleus accumbens and caudate nucleus of rats.
Dafny, N; Dougherty, PM; Qiao, JT; Wiggins, RC, 1990
)
1
"Desipramine has an antiarrhythmic effect in patients with chronic ventricular ectopy, but its clinical utility is limited by adverse effects."( Antiarrhythmic efficacy of desipramine.
Bressler, R; Fenster, PE; Kipps, J, 1989
)
1.3
"Desipramine has been added to methadone maintenance in an attempt to reduce dependence on both substances."( Pharmacological and behavioral treatments of cocaine dependence: controlled studies.
Arndt, IO; Childress, AR; Maany, I; McLellan, AT; O'Brien, CP; Woody, GE, 1988
)
1

Actions

Desipramine (3 mg/kg) or lower doses of paliperidone alone did not affect alcohol drinking. Desipramsine appears to cause myocardial ischemic preconditioning.

ExcerptReferenceRelevance
"Desipramine (3 mg/kg) or lower doses of paliperidone alone did not affect alcohol drinking."( Desipramine enhances the ability of paliperidone to decrease alcohol drinking.
Chau, DT; Dawson, R; Green, AI; Gulick, D; Khokhar, JY, 2015
)
2.58
"Desipramine appears to cause myocardial ischemic preconditioning."( Desipramine pretreatment improves sympathetic remodeling and ventricular fibrillation threshold after myocardial ischemia.
Hu, X; Jiang, H; Liu, W; Wu, X; Yu, L, 2012
)
2.54
"Desipramine-induced increase in aggressive behavior was blocked by phentolamine (3 mg/kg, IP) and yohimbine (0.3 mg/kg, IP), but not prazosin (0.5 mg/kg, IP)."( Desipramine enhances isolation-induced aggressive behavior in mice.
Cai, B; Matsumoto, K; Ohta, H; Satoh, T; Watanabe, H, 1991
)
2.45

Treatment

Desipramine-pretreated thoracic aortas were contracted to a steady-state of 1-2 g with norepinephrine and immersed in mineral oil to prevent diffusion of drugs from the tissue. The treatment did not affect hormonal responses to TRH.

ExcerptReferenceRelevance
"Desipramine pretreatment reduced myocardial HED retention index by 69% and SUV by 85%."( Test-retest repeatability of quantitative cardiac 11C-meta-hydroxyephedrine measurements in rats by small animal positron emission tomography.
Beanlands, RS; DaSilva, JN; Dekemp, RA; Klein, R; Kordos, M; Renaud, JM; Thackeray, JT, 2013
)
1.11
"Desipramine treatment significantly reduced immobility in the tail suspension and forced swim tests, restored sociability in the three-chambered social approach task and reversed impairments in contextual fear conditioning in En2−/− mice."( Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.
Brielmaier, J; Crawley, JN; DiCicco-Bloom, E; Matteson, PG; Millonig, JH; Senerth, JM; Silverman, JL, 2014
)
1.56
"Desipramine treatment did not decrease escape latency times for PND 21 rats, but did decrease times for PND 28 and adult animals."( Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats.
Anderson, JC; Bylund, DB; El Refaey, H; Happe, HK; Petty, F; Reed, AL, 2009
)
1.35
"Both Desipramine and FTY720 treatment reduced ASMase without significant inhibition of other lysosomal hydrolases but most hydrolases showed increased secretion (up to a 50% increase) providing more evidence of lysosomal disruption by these drugs."( Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.
Dawson, G; Qin, J, 2011
)
0.82
"Desipramine treatment before acute myocardial ischemia can decrease infarct size, improve sympathetic remodeling, and increase VFT and electrical stability of ischemic hearts."( Desipramine pretreatment improves sympathetic remodeling and ventricular fibrillation threshold after myocardial ischemia.
Hu, X; Jiang, H; Liu, W; Wu, X; Yu, L, 2012
)
2.54
"Desipramine treatment had no effect in sham or saline control animals but attenuated the reduction of sympathetic neurotransmitter profiles in the left ventricles of animals with rapid cardiac pacing and NE infusion."( Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion.
Himura, Y; Kashiki, M; Liang, CS; Stevens, SY; Yatani, A, 2003
)
2.48
"Desipramine treatment appeared to result in decreases in alcohol consumption in nonalcoholic patients with depression. "( Depressive symptoms and alcohol consumption among nonalcoholic depression patients treated with desipramine.
Bagby, RM; Goldstein, BI; Joffe, RT; Levitt, A; Schaffer, A; Wesson, V; Zaretsky, A, 2004
)
1.98
"Desipramine treatment produced significant NE uptake inhibition as evidence by an exaggerated pressor response and a greater increase of myocardial interstitial NE in response to intravenous NE infusion but no significant effects on cardiac function or hemodynamics in sham-operated or CHF animals."( Cardiac sympathetic neuroprotective effect of desipramine in tachycardia-induced cardiomyopathy.
Fukuoka, S; Iwai, C; Liang, CS; Mao, W; Stevens, SY, 2006
)
1.31
"Desipramine treatment was associated with decreased 6-(18)F-fluorodopamine-derived radioactivity in the heart, renal cortex, and thyroid gland but not in the liver, spleen, renal pelvis, or salivary glands. "( Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure.
Goldstein, DS; Tipre, DN, 2005
)
1.77
"Desipramine treatment produced significant increases in urinary norepinephrine (NE) and normetanephrine (NMN) and plasma NE at Weeks 4 and 6, but not at Week 1."( Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).
Alpert, J; Hennen, J; Koutsos, M; McHale, N; Mooney, JJ; Pappalardo, K; Samson, JA; Schildkraut, JJ, 2008
)
1.32
"desipramine) treatment (both 10 mg/kg; 20 mg/kg x 21 days)."( Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.
Harvey, BH; Korff, S; Stein, DJ, 2008
)
1.07
"Desipramine treatment normalized depressive-like behavior and elevated the dopaminergic mesolimbic activity, although not to control levels."( VTA dopamine neuron bursting is altered in an animal model of depression and corrected by desipramine.
Dremencov, E; Friedman, A; Friedman, Y; Yadid, G, 2008
)
1.29
"Desipramine-treated subjects had decreased uptake but normal loss of 6-[(18)F]fluorodopamine-derived radioactivity."( Cardiac sympathetic hypo-innervation in familial dysautonomia.
Axelrod, FB; Eldadah, B; Goldstein, DS; Sharabi, Y, 2008
)
1.07
"Desipramine-pretreated thoracic aortas were contracted to a steady-state of 1-2 g with norepinephrine and immersed in mineral oil to prevent diffusion of drugs from the tissue."( Vasoconstrictor effects of aldosterone in isolated vascular tissue.
Drayer, JI; Purdy, RE; Weber, MA, 1982
)
0.99
"4. Desipramine treatment did not affect hormonal responses to TRH."( REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder.
Chen, CC; Chicz-Demet, A; Demet, EM; Kauffmann, CD; Reist, C, 1995
)
0.81
"Desipramine treatment decreased both beta-adrenoceptor-elicited cyclic AMP accumulation (-37%) and beta-adrenoceptor density (-29%), whereas citalopram was without effect."( Cyclic AMP and inositol phosphate accumulations in rat brain cortical slices following chronic citalopram or desipramine administration.
Morin, D; Sapena, R; Tillement, JP; Zini, R, 1994
)
1.22
"Desipramine-treated depressed patients were more satisfied and were rated as more improved."( A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression.
Cutler, RB; Kocsis, JH; Mason, BJ; Ritvo, EC, 1996
)
1.28
"Desipramine treatment decreases the neuronal density of both cerebellar high- and low-affinity sites and only the forebrain high-affinity site."( Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes.
Morin, C; Morin, D; Sapena, R; Tillement, JP; Zini, R, 1996
)
2.46
"Desipramine pretreatment markedly reduced (> 60%) myocardial retention of both PHEN and HED."( Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons.
Chiao, PC; Corbett, JR; del Rosario, RB; Gildersleeve, DL; Raffel, DM; Schwaiger, M; Wieland, DM, 1996
)
1.02
"With desipramine pretreatment (n = 7), accumulation of [131I]MIBG decreased in all areas."( Cardiac sympathetic nerve function assessed by [131I]metaiodobenzylguanidine after ischemia and reperfusion in anesthetized dogs.
Arai, M; Becker, LC; Duncker, CM; Takatsu, H,
)
0.59
"Desipramine pretreatment reduced the time spent immobile in rats of the 2 alcohol-nonpreferring lines (i.e., the NP and LAD rats), but had no significant effect in rats of the 2 alcohol-preferring lines (the P and HAD rats)."( Comparison of rats selectively bred for high and low ethanol intake in a forced-swim-test model of depression: effects of desipramine.
Froehlich, JC; Godfrey, CD; Li, TK; Murphy, JM; Stewart, RB, 1997
)
1.23
"In desipramine-treated rats (10 mg/kg, 21 days), but not in fluoxetine-treated ones (3 mg/kg, 14 days), the effect of clonidine was attenuated in cortex (12% and 18%) and only for dopa synthesis in hippocampus (31%)."( Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo.
Esteban, S; García-Sevilla, JA; Lladó, J; Sastre-Coll, A, 1999
)
0.82
"Desipramine pretreatment, to block 6-OHDA uptake and prevent sympathectomy, completely blocked the 6-OHDA-induced effects, demonstrating that the destruction of NA nerve fibers is required."( Alterations in T lymphocyte activity following chemical sympathectomy in young and old Fischer 344 rats.
Bellinger, DL; Felten, DL; Madden, KS; Stevens, SY, 2000
)
1.03
"Desipramine treatment instituted at a daily dosage of 75 mg for depressive equivalents of head, chest, and abdominal pain was increased to 1,000 mg daily over a 12-year interval with minimal side effects."( Withdrawal from long-term high-dose desipramine therapy. Clinical and biological changes.
Brown, GM; Gupta, RN; Harman, J; Moldofsky, H; Murphy, JT; Stancer, HC, 1978
)
1.25
"Desipramine treatment was associated with significant increases in pulse, reclining systolic and diastolic blood pressures, and orthostatic hypotension."( Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa.
Hadigan, CM; Walsh, BT; Wong, LM, 1992
)
1.26
"Desipramine treatment which did not alter Bmax values, increased the proportion of alpha 1a and decreased alpha 1b binding sites."( The effect of reserpine, desipramine and thyroid hormone on alpha 1a- and alpha 1b-adrenoceptor binding sites: evidence for a subtype-specific regulation.
Gross, G; Hanft, G, 1990
)
1.3
"Desipramine-treated subjects showed gradual improvement over the course of the study, and the improvement in week 1 was not so strongly predictive of overall improvement."( Antidepressant or antianxiety? A study of the efficacy of antidepressant medication.
Edwards, J; Fawcett, J; Fogg, L; Kravitz, HM, 1990
)
1
"Desipramine treatment (3.2-10.0 mg/kg per day) suppressed cocaine self-administration (P less than 0.01) without a concomitant suppression of food-maintained responding in one of five subjects."( Desipramine effects on cocaine self-administration by rhesus monkeys.
Bree, MP; Lukas, SE; Mello, NK; Mendelson, JH, 1990
)
2.44
"Desipramine treatment did not have a significant effect on the swimming durations of group-housed rats."( Effects of social isolation on brain catecholamines and forced swimming in rats: prevention by antidepressant treatment.
Henderson, K; Heritch, AJ; Westfall, TC, 1990
)
1
"Desipramine-treated subjects attained contiguous periods of abstinence substantially more frequently than subjects receiving lithium or placebo."( Desipramine facilitation of initial cocaine abstinence.
Byck, R; Gawin, FH; Jatlow, PI; Kleber, HD; Kosten, TR; Morgan, C; Rounsaville, BJ, 1989
)
2.44
"Desipramine-treated rats did not learn the task in contrast to control animals."( Effects of desipramine on rat behavior are prevented by concomitant treatment with ethanol.
Rommelspacher, H; Widjaja, S; Wolffgramm, J, 1989
)
1.39
"Desipramine pretreatment caused a small, but significant, decrease in the depression of locomotor activity, but no change in the hypothermic action of FG7142."( Chronic desipramine treatment prevents the upregulation of cortical beta-receptors caused by a single dose of the benzodiazepine inverse agonist FG7142.
Little, HJ; Stanford, SC; Taylor, SC, 1987
)
1.43
"Desipramine treatment invariably caused decreased food intake and weight loss."( Effects of chronic amitriptyline and desipramine on food intake and body weight in rats.
Coscina, DV; Nobrega, JN, 1987
)
1.27
"Pretreatment with desipramine dramatically promoted metastasis formation and increased mortality rate but inhibited primary tumor growth in young males."( Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice.
Arteta, B; Basta-Kaim, A; Budziszewska, B; Grygier, B; Kołaczkowska, E; Kubera, M; Lasoń, W; Leśkiewicz, M; Maes, M; Majewska, M; Szczepanik, M; Urbańska, K,
)
0.73
"Treatment with desipramine results in differing degrees of subjective side effects and changes in vital signs across the life cycle. "( Side effects of desipramine and age.
Bilich, C; Galanter, CA; Walsh, BT, 2002
)
1.01
"Treatment with desipramine or phenelzine of corticosterone pellet-implanted rats reversed the corticosterone-induced decrease in total brain-derived neurotrophic factor expression in both brain areas; however, fluoxetine reversed the decrease only partially in hippocampus."( Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone.
Dwivedi, Y; Pandey, GN; Rizavi, HS, 2006
)
0.67
"Treatment with desipramine (20mg/kg, i.p.) caused a reduction in immobility time in C57BL/6J mice if the animals were tested at 30 degrees C water temperature, with no effect at 25 degrees C and no effects on forced swim stress-induced corticosterone secretion."( Increased water temperature renders single-housed C57BL/6J mice susceptible to antidepressant treatment in the forced swim test.
Bächli, H; Habersetzer, U; Steiner, MA; Wotjak, CT, 2008
)
0.69
"Treatment with desipramine or imipramine, however, was not effective at reducing immobility in the 21-day-old rats."( Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.
Bylund, DB; Happe, HK; Petty, F; Reed, AL, 2008
)
0.69
"Treatment with desipramine in combination with prazosin, an alpha 1 antagonist, did not accelerate the down-regulation of 5HT2 receptors induced by antidepressants."( Rapid down-regulation of serotonin2 receptor binding during combined administration of tricyclic antidepressant drugs and alpha 2 antagonists.
Crews, FT; Scott, JA; Shorstein, NH, 1983
)
0.61
"Pretreatment with desipramine, 5 mg/kg subcutaneously for 16 days, accelerated baseline HR and reduced cardiovascular actions of clonidine."( Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats.
Cloutier, G; Cubeddu, LX; Grippo, R; Gross, K; Harden, TK; Knowlton, G; Lerea, L; Shakarjian, M; Stat, M; Tanner, L, 1984
)
0.59
"Pretreatment with desipramine increases the calorigenic action of noradrenaline and accelerates its onset and its dying down simultaneously."( [Calorigenic action of dopamine and dobutamine].
Ankermann, H; Ankermann, I, 1983
)
0.59
"treatment with desipramine (50 micrograms/kg)."( 5-hydroxytryptamine inhibits pressor responses to preganglionic sympathetic nerve stimulation in pithed rats.
Castillo, C; Contreras, J; López-Muñoz, FJ; Perusquía, M; Ramŕiez-San Juan, E; Terrón, JA; Villalón, CM, 1995
)
0.63
"Treatment with desipramine (n = 26) did not alter significantly any of the model parameters and had no effect on circadian variability in any patient group."( Disruption of circadian MHPG rhythmicity in major depression.
DeMet, E; Gwirtsman, HE; Halaris, A; Piletz, JE, 1994
)
0.63
"Treatment with desipramine or imipramine caused major alterations in the concentrations of central norepinephrine or 5-HT and its metabolite, respectively."( Regional differences in the levels of biogenic amines and their metabolites in rat brain after tricyclic antidepressant treatments.
Chung, MY; Hong, SS; Kim, DG; Yoo, KJ, 1993
)
0.63
"Treatment with desipramine significantly increased the incidence, but not the number, of colon tumors in week 35."( Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane.
Baba, M; Iishi, H; Taniguchi, H; Tatsuta, M, 1993
)
0.89
"Pretreatment with desipramine and mianserin in combination induced the most intense 5-HT syndrome and the greatest fall in colonic temperature after injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)."( Chronic, combined treatment with desipramine and mianserin: enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2 receptor interaction in rats.
Lund, A; Mjellem, N, 1993
)
0.89
"Pretreatment with desipramine (0.5 mg/kg), a tricyclic antidepressant drug which interacts with a binding site associated with norepinephrine reuptake, markedly decreased cardiac uptake of 6-[18F]FDA and (-)-6-[18F]FNE."( Comparison of high specific activity (-) and (+)-6-[18F]fluoronorepinephrine and 6-[18F]fluorodopamine in baboons: heart uptake, metabolism and the effect of desipramine.
Dewey, SL; Ding, YS; Fowler, JS; Gatley, SJ; King, PT; Logan, J; Schlyer, DJ; Volkow, ND; Wolf, AP, 1993
)
0.81
"Pretreatment with desipramine had no effect on radioactivity in lung."( [11C]metaraminol, a false neurotransmitter: preparation, metabolite studies and positron emission tomography examination in monkey.
Farde, L; Halldin, C; Någren, K; Suhara, T; Swahn, CG, 1996
)
0.62
"Pretreatment with desipramine, an inhibitor of norepinephrine reuptake, potentiated the analgesic effect of i.t."( Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE, 1996
)
0.62
"3. Treatment with desipramine decreased the potency (increased the EC50) of clonidine and xylazine by about 12 and 9 fold respectively."( Modelling the changes induced by chronic desipramine treatment on the factors governing the agonism at prejunctional alpha 2-adrenoceptors.
Badia, A; Giraldo, J; Sallés, J; Vila, E, 1996
)
0.88
"Pretreatment with desipramine greatly blocked the reduction in thymus size and thymocyte number, the changes in thymocyte subpopulations, the percentage of subdiploid (apoptotic) cells and the appearance of DNA fragmented bands."( 6-Hydroxydopamine induces thymocyte apoptosis in mice.
Cheng, JT; Lin, YS; Shen, CL; Tsao, CW, 1996
)
0.62
"Pretreatment with desipramine, an uptake blocker, reduced uptake of radioactivity in myocardium but not in lung, liver, kidney, and muscle."( Biodistribution and metabolism of [N-methyl-11C]m-hydroxyephedrine in the rat.
Camici, PG; Cunningham, VJ; Davenport, RJ; Law, MP; Osman, S; Pike, VW, 1997
)
0.62
"Treatment with desipramine for 24-96 hr had no effect on the expression of GR protein as measured by cytosolic radioligand receptor binding."( Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine.
Miller, AH; Owens, MJ; Pariante, CM; Pearce, BD; Pisell, TL, 1997
)
0.86
"Treatment with desipramine decreased dexmedetomidine-induced loss of righting reflex duration by 67% and eliminated the antinociceptive effect of dexmedetomidine. "( Chronic desipramine treatment desensitizes the rat to anesthetic and antinociceptive effects of the alpha2-adrenergic agonist dexmedetomidine.
Davies, MF; Gonzalez, F; Guo, TZ; Maze, M; Nacif-Coelho, C; Rabin, BC; Reid, K, 1998
)
1.09
"Pretreatment with desipramine reduced the heart half-life of 4-[(18)F]FMR by 90% compared with control."( High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart.
Bottlaender, M; Coulon, C; Crouzel, C; Dollé, F; Fuseau, C; Halldin, C; Langer, O; Loc'h, C; Mazière, B; Ottaviani, M; Valette, H, 2000
)
0.63
"Treatment with desipramine (mean total daily dose, 3.4 mg/kg per day) was well tolerated without meaningful adverse effects. "( A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.
Bearman, SK; Biederman, J; Coffey, B; Crawford, M; Faraone, SV; Geller, D; Spencer, T; Tarazi, R, 2002
)
0.96
"Treatment with desipramine was well tolerated and was associated with robust clinically significant reductions in tic and ADHD symptoms in children and adolescents with chronic tic disorders and ADHD diagnoses."( A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.
Bearman, SK; Biederman, J; Coffey, B; Crawford, M; Faraone, SV; Geller, D; Spencer, T; Tarazi, R, 2002
)
0.96
"Pretreatment with desipramine (blockade of neuronal uptake) in control subjects resulted in a significantly increased inotropic response: delta FS during 40 ng/kg.min epinephrine amounted to 17.6 +/- 3.6% (p less than 0.001 versus untreated controls, NS versus heart transplant recipients) and delta P/D to 1.7 +/- 0.8 mm Hg/mm (p less than 0.001 versus untreated controls, NS versus heart transplant recipients)."( Isolated presynaptic inotropic beta-adrenergic supersensitivity of the transplanted denervated human heart in vivo.
Autenrieth, G; Böhm, M; Erdmann, E; Reichart, B; Schneider, B; von Scheidt, W, 1992
)
0.61
"Treatment with desipramine for 28 days had no effect on the binding parameters in depressed patients when compared to pretreatment values."( Platelet alpha 2-adrenergic receptors in depressed patients and healthy volunteers: the effects of desipramine.
Auffarth, SE; Coote, M; Gupta, RN; Steiner, M; Werstiuk, ES, 1992
)
0.84
"Pretreatment with desipramine (25 mg/kg, systemic) potentiated the action of TFMPP but not CGS 12066B or DOI (or 2-methyl-5-HT)."( Noradrenergic mediation of spinal antinociception by 5-hydroxytryptamine: characterization of receptor subtypes.
Reid, A; Sawynok, J, 1992
)
0.61
"Treatment with desipramine was also found to potentiate and prolong the antinociceptive effect of an acute injection, systemically or intrathecally, of 8-OH-DPAT in the increasing temperature hot plate test."( Desipramine, administered chronically, influences 5-hydroxytryptamine1A-receptors, as measured by behavioral tests and receptor binding in rats.
Hole, K; Lund, A; Mjellem-Jolly, N, 1992
)
2.07
"Pretreatment with desipramine (DMI) resulted in a sparing of noradrenergic neurons from neurotoxic effects."( Injection of 5,7-dihydroxytryptamine into the B3 raphe region of neonatal rat pups induces hyperalgesia but only slight alterations in ingestion-related behaviors.
Enters, EK; Spear, LP; Specht, SM, 1990
)
0.6
"Treatment with desipramine appeared essentially to compensate for reduced social stimulation, blocking isolation-induced noradrenergic neurochemical changes, while having few significant effects on control animals."( Effects of social isolation on brain catecholamines and forced swimming in rats: prevention by antidepressant treatment.
Henderson, K; Heritch, AJ; Westfall, TC, 1990
)
0.62
"Pretreatment with desipramine markedly decreased cardiac positron emission, consistent with dependence of the heart on neuronal uptake (uptake-1) for removal of circulating catecholamines."( Positron emission tomographic imaging of cardiac sympathetic innervation and function.
Bacharach, S; Bacher, J; Chang, PC; Eisenhofer, G; Finn, R; Goldstein, DS; Kirk, KL; Kopin, IJ; Miletich, R, 1990
)
0.6
"Pretreatment with desipramine, a drug known to selectively block neuronal uptake, results in a 92% decrease in tracer accumulation in the myocardium."( Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging.
Gildersleeve, DL; Haka, MS; Jewett, DM; Rosenspire, KC; Schwaiger, M; Van Dort, ME; Wieland, DM, 1990
)
0.6
"Treatment with desipramine (20 mg/kg/d i.p.) for 21 days induces down-regulation of beta-adrenergic receptors and reduces receptor-mediated stimulation of the adenylate cyclase suggesting homologous desensitization. "( Down-regulation of cerebral beta-adrenoceptors induced by long term administration of antidepressants is prevented by ethanol.
Rommelspacher, H; Strauss, S, 1987
)
0.63
"Pretreatment with desipramine prevented the norepinephrine-induced decrease in plasma dihydroxyphenylalanine content, indicating that inhibition of tyrosine hydroxylase required neuronal uptake of norepinephrine."( Source and physiological significance of plasma 3,4-dihydroxyphenylalanine in the rat.
Eisenhofer, G; Goldstein, DS; Kopin, IJ; Ropchak, TG, 1988
)
0.6
"Treatment with desipramine in vivo (10 mg/kg body weight/day) caused a down-regulation of 3H-enkephalinamide binding in the basal ganglia and the hippocampus, while no effects could be observed in the cerebral cortex and the rest of the forebrain."( Opioid peptides and receptors in relation to affective illness. Effects of desipramine and lithium on opioid receptors in rat brain.
Schou, M; Stengaard-Pedersen, K, 1985
)
0.84
"Pretreatment with desipramine abolished DHPG responses to yohimbine while enhancing NE responses."( Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.
Eisenhofer, G; Folio, CJ; Goldstein, DS; Keiser, HR; Kopin, IJ; Stull, R, 1988
)
0.6
"Pretreatment with desipramine abolished the DOPEG response to standing, indicating that orthostasis - induced increases in plasma DOPEG are presynaptic in origin."( Assay of catecholamines and dihydroxyphenylethyleneglycol in human plasma and its application in orthostasis and mental stress.
Gerhardt, T; Graefe, KH; Halbrügge, T; Heidbreder, E; Ludwig, J, 1988
)
0.6
"Treatment with desipramine was significantly more effective than placebo in alleviating abstinence symptoms."( Space-based abstinence: alleviation of withdrawal symptoms in combinative cocaine-phencyclidine abuse.
Giannini, AJ; Giannini, MC; Loiselle, RH, 1987
)
0.61
"Pretreatment with desipramine and pargyline potentiated the lipid effect of electroconvulsive shock in neutral glycerides."( Reduced labeling of brain phosphatidylinositol, triacylglycerols, and diacylglycerols by [1-14C]arachidonic acid after electroconvulsive shock: potentiation of the effect by adrenergic drugs and comparison with palmitic acid labeling.
Bazan, NG; Pediconi, MF; Rodriguez de Turco, EB, 1986
)
0.59
"Pretreatment with desipramine (2.5 mg/kg), an antidepressant characterized as having major noradrenergic effects, did not significantly block the 5-HTP-induced depression."( Blockade of a 5-hydroxytryptophan-induced animal model of depression with a potent and selective 5-HT2 receptor antagonist (LY53857).
Aprison, MH; Fuller, RW; Hingtgen, JN; Mason, NR, 1985
)
0.59
"Cotreatment with desipramine and clomipramine or fluoxetine, inhibitors of NE and 5-HT, respectively had no effect on DA neurotoxicity of MPTP."( Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A, 1985
)
0.6
"Pretreatment with desipramine (10 mg/kg, i.p.) 30 min prior to yohimbine reduced, in rat, or abolished, in mice, the yohimbine-induced elevation of brain DHPG levels."( Further characterization of brain 3,4-dihydroxyphenylethyleneglycol (DHPG) formation: dependence on noradrenergic activity and site of formation.
Godse, DD; Li, PP; Warsh, JJ, 1986
)
0.59
"Pretreatment with desipramine decreased significantly the removal of NE to virtually exactly that of ISO."( Measurement of regional neuronal removal of norepinephrine in man.
Folio, J; Goldstein, DS; Keiser, HR; Kopin, IJ; Levinson, PD; Stull, R; Zimlichman, R, 1985
)
0.59
"Treatment with desipramine did not affect the bradycardia evoked by intrahypothalamic injection of phenylephrine (10 micrograms)."( Effects of desipramine on cardiovascular responses of rats to stimulation of the baroreceptor reflex and of central adrenoceptors.
Poole, S; Stephenson, JD, 1985
)
1

Toxicity

The respective adverse effects of imipramine and desipramne on serum thyroid hormone levels and their accumulation in thyroid were investigated in male Wistar rats. Both medications were well tolerated with drowsiness being the most common side effect of alprazolam, and insomnia, dry mouth, and constipation, the complaints most associated with desiphamine.

ExcerptReferenceRelevance
" LD50 values of three of these compounds were assessed after intraperitoneal administration with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission."( Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Männistö, PT; Törnwall, M, 1991
)
0.28
" over 10 min starting 15 min after administration of a toxic dose of desipramine (DMI)."( Drug-specific F(ab')2 fragment reduces desipramine cardiotoxicity in rats.
Brunn, GJ; Keyler, DE; Pentel, PR; Pond, SM; Ross, CA, 1991
)
0.79
" The side-effect profile of sertraline was similar in young and old, and individual side effects did not make a notable contribution to the discontinuation rate."( Toleration and safety of sertraline: experience worldwide.
Doogan, DP, 1991
)
0.28
" Iatrogenic toxicity resulting from this accumulation of potentially toxic drugs such as CQ within normal cells could complicate the reversal of mdr in vivo."( Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity.
Grogl, M; Long, GW; Martin, SK; Watt, G,
)
0.13
" No adverse reactions were reported, including hypertensive and hyperpyrexic crises."( The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors.
Kahn, D; Opler, LA; Silver, JM, 1989
)
0.28
" As an extension of this hypothesis, the relative resistance of some brain monoaminergic neurons to the toxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may result from the subcellular sequestration of MPP+ in the storage vesicle."( Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.
Daniels, AJ; Diliberto, EJ; Reinhard, JF; Viveros, OH, 1987
)
0.27
" Both medications were well tolerated with drowsiness being the most common side effect of alprazolam, and insomnia, dry mouth, and constipation, the complaints most associated with desipramine."( A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients.
Buchanan, RA; Fleming, JA; Gibson, RE; Keller, FD; Remick, RA, 1988
)
0.71
" The findings indicate that MPTP (or MPP+) is a substrate for the specific DA reuptake system and may explain, in part, its selective toxic effects on DA neurons."( Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A, 1985
)
0.27
" However, five of twenty-nine alprazolam patients had to discontinue therapy because of excessive drowsiness, and two of the alprazolam outpatients had motor vehicle accidents directly related to this adverse event."( A comparison of the safety and efficacy of alprazolam and desipramine in moderately severe depression.
Buchanan, RA; Fleming, JA; Hamilton, P; Keller, FD; Loomer, F; Miles, JE; Remick, RA, 1985
)
0.51
" For some drugs, the required Fab dose may be very high (up to several g/kg) and may have adverse effects of its own."( Toxicity of high doses of polyclonal drug-specific antibody Fab fragments.
Keyler, DE; Landon, J; Pentel, PR; Shelver, WL; Sidki, A, 1994
)
0.29
" These data show that 6-OHDA is not equally toxic to all brain DA neurons in neonates, and that all hypothalamic DA neuronal groups resist the toxicity of 6-OHDA, despite their anatomical and functional differences."( Resistance of hypothalamic dopaminergic neurons to neonatal 6-hydroxydopamine toxicity.
Ibata, Y; Okamura, H; Yokoyama, C, 1993
)
0.29
" Side effect ratings and EKGs were done weekly."( Side effects of methylphenidate and desipramine alone and in combination in children.
Biancaniello, TM; Carlson, GA; Kelly, KL; Pataki, CS; Rapport, MD, 1993
)
0.56
"The uptake and cytotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of the parkinsonism inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were studied in COS-7 cells transiently transfected with the cloned human noradrenaline and dopamine transporters and in permanently transfected SK-N-MC neuroblastoma cells."( Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
Caron, MG; Giros, B; Hornykiewicz, O; Pifl, C, 1996
)
0.29
"The respective adverse effects of imipramine and desipramine on serum thyroid hormone levels and their accumulation in thyroid were investigated in male Wistar rats."( Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration.
Buxeraud, J; Lachâtre, G; Lagorce, JF; Marquet, P; Raby, C; Rousseau, A; Sauvage, MF, 1998
)
0.8
" Group means of side effect ratings and vital signs were compared."( Side effects of desipramine and age.
Bilich, C; Galanter, CA; Walsh, BT, 2002
)
0.66
"Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants."( Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
Alpert, JE; Denninger, JW; Fava, M; Montoya, HD; Nierenberg, AA; Papakostas, GI; Petersen, T,
)
0.13
" This review focuses on the tolerability, occurrence of adverse events, precautions required to prevent severe adverse events, and essential pharmacological interaction in the treatment of ADHD symptoms by non-stimulants."( The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A, 2005
)
0.33
" The tested drugs were very toxic to the protozoan Spirostomum ambiguum and the crustacean Thamnocephalus platyurus with the LC50 values around 1 mg l(-1)."( In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit F Tests.
Nałecz-Jawecki, G, 2008
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Adverse effects were evaluated as well."( A systematic review of the efficacy and safety of desipramine for treating ADHD.
Ghanizadeh, A, 2013
)
0.64
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
"This is the first study to compare frequency of sexual side effect reporting between paroxetine and desipramine."( A Comparison of Sexual Side Effects of Antidepressants With and Without Naltrexone.
Petrakis, I; Ralevski, E; Thapa, M,
)
0.35

Pharmacokinetics

A two compartment population pharmacokinetic model best described desipramine disposition. An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increased in these parameters for sertraline occurred simultaneously with the desiphamine concentration changes.

ExcerptReferenceRelevance
" Significantly higher variability was found in the pharmacokinetic parameters of the metabolite."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.28
"Researchers used population pharmacokinetic parameters and data on the concentration effect relationship from 49 6-13 year old children suffering from enuresis who attended an outpatient psychiatric clinic at University Clinical Hospital in Salamanca, Spain to design rational dosing guidelines of the antidepressant imipramine (IMI) for individual patients."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.28
" Recent pharmacokinetic studies in diverse patient populations such as the depressed elderly, children and alcoholics have revealed decreased clearance of imipramine in the elderly and increased clearance of both imipramine and desipramine in chronic alcoholics."( Clinical pharmacokinetics of imipramine and desipramine.
Pollock, BG; Sallee, FR, 1990
)
0.72
" A relationship between age and kinetic parameters such as area under the curve, elimination phase constant, half-life and total body clearance was observed."( Imipramine pharmacokinetics in depressed geriatric patients.
Baraldo, M; Benetello, P; Furlanut, M; Zara, G, 1990
)
0.28
" There were no indications to assume a changed absorption of imipramine due to vinpocetine as would be reflected in Cmax and tmax values."( Vinpocetine therapy does not change imipramine pharmacokinetics in man.
Braun, W; Grandt, R; Hitzenberger, G; Schmid, R, 1990
)
0.28
" The present studies show that pharmacokinetic variations of imipramine in the brain might correlate with the altered levels of 5-HIAA, NE and MHPG."( Correlative changes of serotonin and catecholamines with pharmacokinetic alterations of imipramine in rat brain.
Kobayashi, A; Nakazawa, K; Sugita, S; Suzuki, S; Yoshida, T, 1989
)
0.28
"The pharmacokinetic differences of tricyclic antidepressants (TCAs) in Asians and Caucasians remain controversial."( Pharmacokinetics of desipramine in Asian and Caucasian volunteers.
Cooper, TB; Gray, GE; Pi, EH; Suckow, RF; Tran-Johnson, TK; Walker, NR, 1989
)
0.6
" In a pharmacokinetic evaluation of patients with depression, we examined single-dose elimination curves before and after a four-week regimen of desipramine treatment."( Determination of serum desipramine and 2-hydroxydesipramine for pharmacokinetic applications by HPLC with ultraviolet detection.
Burton, ME; Kenney, JT; Kolodner, RM; Orsulak, PJ, 1989
)
0.79
"The pharmacokinetic profiles of imipramine (IMI) and its major active metabolites were determined in pregnant rats following an acute 30 mg/kg ip IMI dose."( Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose.
DeVane, CL; Simpkins, JW,
)
0.13
" The mean elimination half-life for imipramine was significantly decreased in alcoholics (8."( Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.
Barnhill, JG; Ciraulo, DA; Jaffe, JH, 1988
)
0.54
" Following a series of controlled dosage decreases, from 400 to 50 mg/day, the patient's steady state serum concentrations fit a nonlinear pharmacokinetic model."( Nonlinear desipramine pharmacokinetics: a case study.
Bishop, DS; Dugas, JE, 1985
)
0.67
" Her elimination half-life for desipramine was found to be greatly prolonged, at approximately 150 hours."( Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman.
Dugas, JE; Glassman, JN; Loyd, DW; Tsuang, MT, 1985
)
0.56
" Tricyclic pharmacokinetic parameters, determined from plasma samples over 48 hours, indicated decreased total body clearance, increased elimination half-life, and higher peak plasma levels during disulfiram treatment."( Pharmacokinetic interaction of disulfiram and antidepressants.
Barnhill, J; Boxenbaum, H; Ciraulo, DA, 1985
)
0.27
"The pharmacokinetic linearity of two single oral doses of desipramine hydrochloride was examined in a parallel study involving 30 subjects."( Pharmacokinetic linearity of desipramine hydrochloride.
Cawein, M; Dusebout, T; Garteiz, D; Okerholm, R; Weiner, D; Wright, G, 1981
)
0.8
" The assessment of TCA actions that may be additive, synergistic, or antagonistic requires precise knowledge of pharmacodynamic potency and control of pharmacokinetic behavior."( Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics.
Lane, EA; Potter, WZ; Rudorfer, MV, 1984
)
0.27
"A review of pharmacodynamic studies of nomifensine in healthy subjects indicates that nomifensine caused neither negative nor positive (euphoric) mood alterations and led to no impairments in various tests of performance and to some improvement in vigilance, attention, and psychomotor performance."( Pharmacodynamics of nomifensine: a review of studies in healthy subjects.
Siegfried, K; Taeuber, K, 1984
)
0.27
"In order to better define the role of pharmacokinetic variation in reported cross-ethnic differences in dosing patterns of some psychoactive drugs, single dose kinetics of the tricyclic antidepressant desipramine (DMI) were studied in 14 Chinese and 16 Caucasian healthy volunteers."( Desipramine pharmacokinetics in Chinese and Caucasian volunteers.
Chang, WH; Lane, EA; Potter, WZ; Rudorfer, MV; Zhang, MD, 1984
)
1.9
" The apparent elimination half-life of imipramine was 20."( Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly.
Forette, F; Gomeni, R; Henry, JF; Hervy, MP; Hrdina, PD; Morselli, PL; Rovei, V, 1980
)
0.26
" Paracetamol, the only metabolised drug which is conjugated for which pharmacokinetic parameters have been accurately determined in obesity, undergoes increased clearance in obese subjects."( Pharmacokinetics of drugs in obesity.
Abernethy, DR; Greenblatt, DJ,
)
0.13
" Nonlinear least-squares regression of concentration-time data indicated that parent drug disposition could be described by a one-compartment open pharmacokinetic model for two subjects and by a two-compartment model for two subjects."( Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers.
DeVane, CL; Jusko, WJ; Savett, M, 1981
)
1.71
"The time course of change in plasma levels of cocaine and its major metabolite benzoylecgonine following 3 mg/kg IV cocaine and the pharmacokinetic interaction between cocaine and several monoamine uptake inhibitors were investigated in conscious rats implanted with arterial and venous cannulae."( Monoamine uptake inhibitors alter cocaine pharmacokinetics.
Goldberg, SR; Tella, SR, 1993
)
0.29
" To delineate the pharmacokinetic mechanisms, we studied the effects of a high-affinity, drug-specific Fab fragment on desipramine (DMI) disposition in rats and on DMI kinetics in the isolated, perfused rat liver."( Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver.
Keyler, DE; Le Couteur, DG; Pentel, PR; Pond, SM; St Peter, JV, 1995
)
0.76
" Nonlinear least-squares fitting of cortical concentration-effect data to the pharmacodynamic Emax model equation after the separate administration of desipramine and desmethyldesipramine generated Emax estimates for desipramine and desmethyldesipramine of approximately 36 and 29%, respectively, and EC50 estimates of 365 and 467 ng/g, respectively."( The pharmacodynamics of desipramine and desmethyldesipramine in rats.
Argenti, D; D'Mello, AP, 1994
)
0.79
" The feasibility of the brain microdialysis method for direct measurement and pharmacokinetic study of imipramine (Imip) and its metabolite desipramine (DMI) was investigated in the rat brain."( Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis.
Ishikawa, K; Sato, Y; Shibanoki, S; Sugahara, M, 1994
)
0.49
"The pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.83
" Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.52
"02), a prolongation in imipramine half-life (from 16."( Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Scordo, MG; Spina, E, 1997
)
0.53
" An approximately 10-fold increase in the Cmax and AUC(24) of paroxetine and an approximately 2-fold increase in these parameters for sertraline occurred simultaneously with the desipramine concentration changes."( Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman, J; Allison, J; Chung, M; Greenblatt, DJ; Harrison, W; Penenberg, D; Preskorn, SH, 1997
)
1.93
"To examine the pharmacokinetic interaction between the selective serotonin reuptake inhibitor sertraline and the tricyclic antidepressants desipramine or imipramine in 12 healthy male subjects."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.75
"Multiple-dose, but not single-dose, treatment with sertraline significantly reduced apparent plasma clearance (CL/F) and prolonged the half-life of desipramine relative to baseline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.75
"This pharmacokinetic interaction is likely the result of an inhibition of CYP2D6 tricyclic metabolism by sertraline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.55
" The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion."( Clinical pharmacokinetics of acamprosate.
Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S, 1998
)
0.3
"DMI pharmacokinetic parameters were calculated from 407 routinely drawn, dose- and weight-normalized serum concentrations in 173 youths receiving DMI (90 children, 83 adolescents; 29 were female, 144 were male)."( Desipramine clearance in children and adolescents: absence of effect of development and gender.
Biederman, J; Cohen, LG; Faraone, SV; Flood, JG; Mick, E; Prince, J; Spencer, TJ; Wilens, TE, 1999
)
1.75
"Mean pharmacokinetic parameters for the entire population included dose (3."( Desipramine clearance in children and adolescents: absence of effect of development and gender.
Biederman, J; Cohen, LG; Faraone, SV; Flood, JG; Mick, E; Prince, J; Spencer, TJ; Wilens, TE, 1999
)
1.75
" We also measured pharmacokinetic parameters: the level of IMI and its metabolite, desipramine (DMI), in the rat plasma and brain (1 h after the forced swimming test)."( Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Daniel, WA; Rogóz, Z; Skuza, G; Wójcikowski, J,
)
0.36
" Measurement of secretion of saliva, Visual Analogue Scale assessment of dryness of mouth and tiredness were carried out on day 7 and day 8 to assess the pharmacodynamic consequences of deramciclane or paroxetine co-administration with desipramine."( Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Anttila, M; Björklund, H; De Bruyn, S; Hänninen, J; Laine, K; Rouru, J; Scheinin, H, 2004
)
0.72
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" Pharmacokinetic parameters of desipramine were analysed according to CYP2D6 category."( Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Bertz, RJ; Furman, KD; Grimm, DR; Holley-Shanks, RR; Katz, DA; Mueller, T; Spear, BB; Williams, LA, 2004
)
0.85
" Since there was no increase in brain imipramine/desipramine or zinc brain concentration after combined zinc and imipramine treatment, the data suggest that pharmacodynamic rather than pharmacokinetic interaction between zinc and imipramine is responsible for behavioral effect in the forced swim test."( Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice.
Baś, B; Dybała, M; Niewiara, E; Nowak, G; Opoka, W; Pomierny, L; Szymura-Oleksiak, J; Wyska, E,
)
0.39
"To determine the potential for pharmacokinetic interaction between nefazodone (NFZ), and desipramine (DMI)."( Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Horst, WD; Khan, AY; Preskorn, SH, 2007
)
0.84
"A single center, open-label, multiple-dose, parallel-group pharmacokinetic trial conducted in 28 healthy male and female subjects."( Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Horst, WD; Khan, AY; Preskorn, SH, 2007
)
0.62
"Pharmacokinetic analysis demonstrated that the addition of NFZ to DMI did not result in any significant changes in the AUC(0-12), Cmax, or tmax of either DMI or 2-OH-DMI."( Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Horst, WD; Khan, AY; Preskorn, SH, 2007
)
0.62
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This study investigated the pharmacokinetic and pharmacological interactions between imipramine and sodium alginate in rats."( Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats.
Aimoto, T; Araki, H; Imai, K; Inoue, N; Suemaru, K; Watanabe, S, 2008
)
0.35
" Following a single method qualification run, the method was applied to the quantitation of pharmacokinetic study samples after oral administration of imipramine to male rats."( Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study.
Fast, DM; Groeber, EA; Pabbisetty, D; Song, W; Steenwyk, RC, 2009
)
0.35
"To develop a population pharmacokinetic model to describe the pharmacokinetics of desipramine in healthy subjects, after oral administration of a 50mg dose."( Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Chien, JY; Gueorguieva, I; Jackson, K; Sinha, VP; Wrighton, SA, 2010
)
2.03
"A two compartment population pharmacokinetic model best described desipramine disposition."( Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Chien, JY; Gueorguieva, I; Jackson, K; Sinha, VP; Wrighton, SA, 2010
)
2.04
"Predicted metabolic drug clearances (CLPT ) were determined using in vitro-in vivo extrapolation coupled with physiological-based pharmacokinetic modelling and simulation (IVIVE-PBPK) in Simcyp®."( Predicted metabolic drug clearance with increasing adult age.
Doogue, MP; Jensen, BP; Patel, F; Polasek, TM; Sorich, MJ; Wiese, MD, 2013
)
0.39
" A single-center, randomized, placebo-controlled, two-way crossover study in 20 healthy male subjects was conducted to evaluate the pharmacokinetic and pharmacodynamic interactions between almorexant and desipramine."( Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Alessi, F; Cruz, HG; Dingemanse, J; Hay, JL; Hoever, P; te Beek, ET; van Gerven, JM, 2014
)
0.8
" The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations."( The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Callegari, E; Nguyen, HQ; Obach, RS, 2016
)
0.87
" The objective of this study was to develop and qualify a physiologically based pharmacokinetic (PBPK) model for desipramine, which accounts for the high Vss of the drug following intravenous and oral administration of doses up to 100 mg."( Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study.
Lukacova, V; Samant, TS; Schmidt, S, 2017
)
0.87
"We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)."( Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019
)
0.51

Compound-Compound Interactions

The effect of chronic ethanol exposure alone or in combination with desipramine on agonist and antagonist binding to beta-adrenoceptors was studied in membrane preparations from rat frontal cortex and hippocampus. The semi-mechanistic population model developed is suitable to describe the pharmacokinetic behaviour of desiphamine for the dose routinely used in drug-drug interaction studies.

ExcerptReferenceRelevance
"The effect of chronic ethanol exposure alone or in combination with desipramine on agonist and antagonist binding to beta-adrenoceptors was studied in membrane preparations from rat frontal cortex and hippocampus."( Effects of chronic exposure to ethanol alone and in combination with desipramine on beta-adrenoceptors of rat brain.
Gurguis, G; Karanian, J; Linnoila, M; Potter, WZ; Turkka, J, 1990
)
0.75
"The drug-drug interactions with fluoxetine, a pure serotonergic reuptake blocker with a unique profile of side effects, have not been studied adequately."( Drug-drug interactions of fluoxetine with tricyclics.
von Ammon Cavanaugh, S, 1990
)
0.28
" There was no change in alpha MT6s excretion, and thus the previously reported potentiation of the efficacy of tricyclic antidepressants in combination with T3 does not appear to be mediated through an alteration in noradrenergic neurotransmission."( A study of the effects of desipramine treatment alone and in combination with L-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients.
Arendt, J; Bearn, J; Checkley, SA; Franey, C, 1989
)
0.58
" This treatment was combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day)."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.27
" Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine."( Trypanocidal resistance in Trypanosoma evansi in vitro: effects of verapamil, cyproheptidine, desipramine and chlorpromazine alone and in combination with trypanocides.
Anene, BM; Anika, SM; Chukwu, CC; Ross, CA, 1996
)
0.71
" In our search for a reporter gene that lacks these limitations, we have evaluated the feasibility of the human norepinephrine transporter (hNET) as a reporter gene in combination with the reporter probe 11C-m-hydroxyephedrine (mHED) for PET."( The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy.
Beerens, AM; Buursma, AR; de Vries, EF; Haisma, HJ; Hospers, GA; Rots, MG; Vaalburg, W; van Waarde, A, 2005
)
0.33
"The purpose of this study was to propose a new method to predict in vivo drug-drug interactions (DDIs) for a high clearance drug from in vitro data."( Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model.
Kohno, Y; Nagata, K; Suzuki, A; Yamamoto, T; Yamazoe, Y, 2006
)
0.33
"There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure."( An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Generaux, GT; McConn, DJ; Muir, KT; Reese, MJ; St John-Williams, L; Wurm, RM, 2008
)
0.82
"A number of antidepressants inhibit the activity of the cytochrome P450 2D6 enzyme system, which can lead to drug-drug interactions."( An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Burczynski, ME; Connolly, SM; Fatato, P; Guico-Pabia, C; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, R, 2008
)
0.55
"A novel method for the prediction of drug-drug interaction has been established based on the in vitro metabolic stability in the "serum incubation method" using cryopreserved human hepatocytes suspended in 100% human serum."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.35
" 25 mg may be safely administered with agents metabolized through the CYP2D6 pathway, but vigilance for drug interaction is warranted in patients with advanced malignancies."( Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Abbas, R; Boni, J; Burns, J; DeMaio, W; Hoffmann, M; Hug, B; Jordan, R; Leister, C, 2009
)
0.71
"We tested the effects of intra-lateral septal infusions of neuropeptide Y (NPY) combined with systemic injections of topiramate in the DRL-72s paradigm and the elevated plus-maze test in male Wistar rats."( Antidepressant-like or anxiolytic-like actions of topiramate alone or co-administered with intra-lateral septal infusions of neuropeptide Y in male Wistar rats.
Jaramillo, MT; Molina-Hernández, M; Olivera-Lopez, JI; Téllez-Alcántara, NP, 2010
)
0.36
" The semi-mechanistic population model developed is suitable to describe the pharmacokinetic behaviour of desipramine for the dose routinely used in drug-drug interaction (DDI) studies."( Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Chien, JY; Gueorguieva, I; Jackson, K; Sinha, VP; Wrighton, SA, 2010
)
2.02
"Predictions of drug-drug interactions (DDIs) are commonly performed for single inhibitors, but interactions involving multiple inhibitors also frequently occur."( In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
Isoherranen, N; Lutz, JD, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Based on these results, a series of clinical drug-drug interaction (DDI) studies were conducted to evaluate the effect of ivacaftor on sensitive substrates of CYP2C8 (rosiglitazone), CYP3A (midazolam), CYP2D6 (desipramine), and P-gp (digoxin)."( Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
Chavan, AB; Dubey, N; Gilmartin, GS; Higgins, M; Li, C; Luo, X; Mahnke, L; Robertson, SM, 2015
)
0.6
" To create a safer clozapine-like drug, we tested whether the antipsychotic iloperidone, a drug that combines a weak dopamine D2 receptor blockade and a potent norepinephrine alpha-2 receptor blockade would reduce alcohol drinking, and whether its effect on alcohol drinking could be increased if combined with an agent to facilitate norepinephrine activity."( Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster.
Green, AI; Khokhar, JY, 2016
)
0.71

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of an orally administered dose of imipramine ranged between 29."( Plasma levels of imipramine and desipramine in man after different routes of administration.
Johansson, R; Nagy, A, 1975
)
0.54
"Twelve healthy male subjects completed this randomized, placebo controlled, four-period crossover trial to determine the effect of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine."( Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Danis, M; Dukes, GE; Hak, LJ; Han, YH; Hermann, DJ; Hussey, EK; Krol, TF; Powell, JR, 1992
)
0.28
" AUCs of day 10 without and of day 21 during concomitant vinpocetine treatment were compared, demonstrating the independence of imipramine's bioavailability from concomitant vinpocetine treatment."( Vinpocetine therapy does not change imipramine pharmacokinetics in man.
Braun, W; Grandt, R; Hitzenberger, G; Schmid, R, 1990
)
0.28
" The authors recommend routine monitoring of doxepin levels in the elderly and question poor bioavailability or absorption of this tricyclic antidepressant in some patients."( Comparative plasma levels of doxepin and desipramine in the elderly.
Ancill, RJ; Gosselin, C, 1989
)
0.54
" imipramine doses indicated no difference in absolute bioavailability between the elderly and young of either sex."( Imipramine and desipramine disposition in the elderly.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1985
)
0.62
" It was assumed that pretreatment with cimetidine, because of its inhibition of metabolic pathways of both demethylation and hydroxylation as well as its ability to reduce hepatic extraction of these drugs, would increase bioavailability and decrease clearance of both drugs."( Cimetidine interaction with imipramine and nortriptyline.
Henauer, SA; Hollister, LE, 1984
)
0.27
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" This study describes the bioavailability of 3 formulations of imipramine."( Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001
)
0.31
" The pharmacokinetic characteristics, Cmax, AUC, t1/2 and tmax were determined and the relative bioavailability of the two coated tablet formulations was calculated with the aqueous solution as reference."( Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001
)
0.31
"The monoamine theory of depression proposes decreased bioavailability of monoamines, such as norepinephrine (NE), as the underlying cause of depression."( An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission.
Ignatowski, TA; Reynolds, JL; Spengler, RN; Sud, R, 2005
)
0.61
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37

Dosage Studied

Twenty-six symptomatic subjects who met research diagnostic criteria for major affective disorder were treated for 3 wk with a fixed dosage schedule of desipramine (DMI) to a maximum of 200 mg/day. Ten initial nonresponders were converted to responders when dosage increase raised desiphamine plasma concentration to 125 ng/mL or above.

ExcerptRelevanceReference
" In determination of the optimal individual dosage must continue to be an empirical process based on clinical observations and experience."( [Correlation between plasma concentration and clinical effect of neuroleptics and antidepressants].
Modestin, J; Petrin, A, 1976
)
0.26
" The dose-response curve for the chronotropic action of phenylephrine was parallel to that of isoprenaline, whilst the dose-response curve for the inotropic action of phenylephrine was less steep than that of isoprenaline."( Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog.
Endoh, M; Shimizu, T; Yanagisawa, T, 1978
)
0.26
" Knowledge of the drug dose-response curve and its levels in blood may enable the physician to convert a patient from a "nonresponder" into a "responder."( High dose desipramine, plasma drug levels and clinical response.
Amsterdam, J; Brunswick, DJ; Mendels, J, 1979
)
0.66
" Desipramine treatment instituted at a daily dosage of 75 mg for depressive equivalents of head, chest, and abdominal pain was increased to 1,000 mg daily over a 12-year interval with minimal side effects."( Withdrawal from long-term high-dose desipramine therapy. Clinical and biological changes.
Brown, GM; Gupta, RN; Harman, J; Moldofsky, H; Murphy, JT; Stancer, HC, 1978
)
1.44
"In cumulative dose-response studies, strips from bladder neck of rabbit were significantly more sensitive to stimulation with noradrenaline, phenylephrine, and methoxamine than were strips from detrusor."( A difference in sensitivity to alpha-adrenergic agonists exhibited by detrusor and bladder neck of rabbit.
Awad, SA; Carro-Ciampi, G; Dean, DM; Downie, JW, 1975
)
0.25
" This behavioral syndrome, characterized by tremor and muscle twitches (myoclonus), showed a clear dose-response relationship with 5,7-DHT as well as with 5-HTP."( Inhibition of 5,7-dihydroxytryptamine-induced supersensitivity to 5-hydroxytryptophan in mice by treatment with cycloheximide.
Baldessarini, RJ; Campbell, A; Sperk, G; Stewart, RM, 1978
)
0.26
" Cocaine (2 x 10(-6) M and 10(-5) M) produced 2 and 7 fold shifts to the left of the dose-response curve to (-)-noradrenaline recorded isotonically in isolated splenic capsular strips of the cat."( Investigation of the role of calcium in the supersensitivity produced by cocaine in cat spleen strips.
Summers, RJ; Tillman, J, 1979
)
0.26
"Tricyclic antidepressant plasma levels were measured in patients and healthy subjects after a single dise of desmethylimipramine (DMI) or imipramine (IMI) and after chronic dosing to steady states."( Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data.
Amsterdam, JD; Brunswick, DJ; Mendels, J; Stern, SL, 1979
)
0.26
" of thiabendazole occurred 2--4 h after oral dosing (50--200 mg/kg) to rats."( Inhibition of thiabendazole metabolism in the rat.
Cawthorne, MA; Green, J; Parke, DV; Wilson, CG, 1979
)
0.26
" Low concentrations of (--)-cocaine or its stereoisomer, (4)-pseudococaine, produced shifts to the right of the 5-HT dose-response curves on heart and ileum with no depression of the maximum responses to electrical stimulation or dimethylphenylpiperazinium remained unaffected."( Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds.
Fozard, JR; Mobarok Ali, AT; Newgrosh, G, 1979
)
0.26
" Plasma levels of the tricyclics were relatively stable on both dosage schedules due to the long plasma half-lives of these drugs."( Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time.
Biggs, JT; Meyer, DA; Preskorn, SH; Rosen, SH; Ziegler, VE, 1978
)
0.61
" Following each treatment the effect of tyramine was diminished, with a shift to the right in the tyramine dose-response curve."( Influence of nomifensine and desipramine on tyramine pressor responses in healthy volunteers.
McEwen, J, 1977
)
0.55
" Nevertheless the effectiveness of repeated activated charcoal dosage in lowering antidepressant concentrations of visceral organs is unpredictable."( Treatment of experimental imipramine and desipramine poisoning in the rat.
Olling, M; Rauws, AG, 1976
)
0.52
" At this time DMI treatment of pineal glands taken from intact rats shifted the dose-response curve for epinephrine (EPI) stimulation of N-acetyltransferase activity by two orders of magnitude, but caused only a slight change in the dose-response curve for isoproterenol, which is not taken up into nerve endings."( Sympathetic nerve endings in the pineal gland protect against acute stress-induced increase in N-acetyltransferase (EC 2.3.1.5.) activity.
Klein, DC; Parfitt, AG, 1976
)
0.26
"The effect of desipramine on the cumulative dose-response curves of noradrenaline and potassium (K+) was examined on the isolated rat vas deferens."( Persistent enhancement of potassium-induced responses of the rat vas deferens by desipramine.
Schneider, D; Swamy, VC, 1976
)
0.84
" Both drugs also shift to the left the dose-response curves for noradrenaline and adrenaline on isolated strips, cocaine being most potent."( Uptake and release of catecholamines in sympathetic nerve fibres in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" For the inhibition of the hypotensive action of clonidine by protriptyline a parallel shift of the dose-response curve was obtained, indicating the possibility of a competitive antagonism."( Interaction between centrally acting hypotensive drugs and tricyclic antidepressants.
van Zwieten, PA, 1975
)
0.25
" Included are the drugs' putative mechanisms of action, pharmacology, toxicology, indications for their use, short-term and long-term actions, adverse effects, specific dosing regimens, therapeutic monitoring techniques, alternative medications, and drug interactions."( Pharmacologic treatment of attention deficit hyperactivity disorder.
Greenhill, LL, 1992
)
0.28
" The presence of PG generally enhanced the absorption of each drug, and the degree of enhancement appeared to be related to the percentage of PG in the dosing solution."( Propylene glycol as a vehicle for percutaneous absorption of therapeutic agents.
Bailey, DN,
)
0.13
" Mianserin was given in the fixed dosage of 60 mg per day, whereas the dose of imipramine was adjusted to yield the optimal plasma concentration of imipramine plus desipramine of 400-600 nmol."( Lack of effect of mianserin on the symptoms of diabetic neuropathy.
Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T; Tuxen, C, 1992
)
0.48
" The population pharmacokinetic parameters obtained in the study permit dosage individualisation using a bayesian algorithm."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.28
"Researchers used population pharmacokinetic parameters and data on the concentration effect relationship from 49 6-13 year old children suffering from enuresis who attended an outpatient psychiatric clinic at University Clinical Hospital in Salamanca, Spain to design rational dosing guidelines of the antidepressant imipramine (IMI) for individual patients."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.28
" The imipramine dosage was flexible to give a plasma concentration around 200 nmol/l and mianserin was given at a fixed dosage of 30 mg daily."( Combined treatment with imipramine and mianserin. A controlled pilot study.
Bech, P; Clemmesen, L; Klysner, R; Lauritzen, L; Loldrup, D; Lunde, M; Schaumburg, E; Waarst, S, 1992
)
0.28
" When imipramine or desipramine are to be coadministered with fluoxetine, a lower dosage may be needed to maintain steady-state concentrations and to avoid undesirable side effects caused by excessive tricyclic concentrations."( Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.
Bergstrom, RF; Lemberger, L; Peyton, AL, 1992
)
0.61
"Three methods for estimating maintenance dosage requirements of imipramine were compared retrospectively in 146 enuretic patients."( Dosage optimization methods applied to imipramine and desipramine in enuresis treatment.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.53
"A monoclonal antibody was used to study the dose-response relationship for antibody-mediated redistribution of tricyclic antidepressants (TCA) in rats."( Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship.
Brunn, GJ; Gilbertson, DG; Keyler, DE; Matta, SG; Milavetz, JM; Pentel, PR; Pond, SM,
)
0.13
" The incidence of side effects was related to both dosage and dosage regimen."( Toleration and safety of sertraline: experience worldwide.
Doogan, DP, 1991
)
0.28
" Mean plasma concentration of desipramine in a subsample of our subjects was less than that recommended for treatment of depression, thus the dosage of desipramine may have been subtherapeutic."( Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence.
Brown, BS; Haertzen, CA; Hess, JM; Jaffe, JH; Kolar, AF; Mahaffey, JR; Weddington, WW, 1991
)
0.86
" Redetermination of the dose-response function for clenbuterol, following 2 weeks of repeated daily administration, showed that clenbuterol no longer affected DRL behavior at doses up to 3 mg/kg."( Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol.
O'Donnell, JM, 1990
)
0.28
" The steepness of the DMI dose-response curve was examined by administering DMI alone (without antibody) at various doses to rats."( Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats.
Brunn, GJ; Keyler, DE; Pentel, PR; Pond, SM, 1991
)
0.54
" Desipramine plasma levels drawn 24 hours after an initial standardized dose were used to rapidly adjust desipramine dosage and compensate for the interactive effects of fluoxetine on desipramine levels in the blood."( A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.
Bowers, MB; Jatlow, PI; Mazure, CM; Nelson, JC, 1991
)
1.43
" Daily dosage at bedtime was constant for the final 3 weeks of the 5-week study (mean, [SD] 169."( 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults.
Cooper, TB; Johnson, MH; Nelson, LD; Ribner, HS; Stern, SL; Suckow, RF, 1991
)
0.7
" Full dose-response curves to noradrenaline, vasopressin and potassium chloride were established."( Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine.
Fraser, R; Kenyon, CJ; Russo, D, 1990
)
0.49
" Complete dose-response functions for cocaine (0."( The effects of cocaine on food intake of baboons before, during, and after a period of repeated desipramine.
Fischman, MW; Foltin, RW; Nautiyal, C, 1990
)
0.5
" Side effects limited desipramine dosage in half of the treated patients."( Antidepressant pharmacotherapy of depression associated with multiple sclerosis.
Schiffer, RB; Wineman, NM, 1990
)
0.59
" The imipramine dosage was significantly higher in the combined treatment group than in the imipramine-only group."( Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder.
Brown, CS; Cold, JA; Froemming, JH; Jabbour, JT; Self, TH; Wells, BG, 1990
)
0.28
" Compared with earlier results obtained with imipramine dosed on the basis of plasma level monitoring, clomipramine and desipramine on fixed doses appeared less efficacious whereas the side effect profiles were the same."( Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T, 1990
)
0.83
" The results obtained show that the variables which are most associated with the reduction of enuresis are, in decreasing order: the dosage of imipramine administered, the duration of treatment, compliance and the level/dose ratio for the sum of the drug and metabolite levels."( The influence of clinical and pharmacological factors on enuresis treatment with imipramine.
Domínguez-Gil, A; Fernández de Gatta, MM; Galindo, P; García, MJ; Gutierrez, J; Rey, F; Tamayo, M, 1990
)
0.28
" (standard deviation) in both dosage groups was 37."( Plasma versus bone marrow desipramine: a comparative study.
Wahba, WW; Westwood, SE; Winek, CL, 1990
)
0.58
" Gangliosides, which had no effect per se, showed a clear dose-response relationship in enhancing the anti-immobility effect of desipramine."( Gangliosides enhance the anti-immobility response elicited by several antidepressant treatments in mice.
Basso, AM; Córdoba, NE; Molina, VA; Orsingher, OA, 1990
)
0.48
" Each subject was then maintained on daily doses of desipramine for 3 to 4 weeks, after which a second cocaine self-administration dose-response curve was generated under desipramine maintenance."( Effects of desipramine maintenance on cocaine self-administration by humans.
Fischman, MW; Foltin, RW; Nestadt, G; Pearlson, GD, 1990
)
0.92
"1 mg/kg) enhanced clonidine-induced hypothermia and hypoactivity, chronic dosing (twice daily for 14 days) with desipramine (10 mg/kg) or rolipram (5 mg/kg) antagonized these behavioural effects."( Effect of long-term rolipram administration on the sensitivity of alpha 2-adrenoceptors in rat brain.
Luscombe, DK; Mustafa, MR; Stolz, JF, 1988
)
0.49
"Thirty-seven children (6-13 years old), receiving a flexible dosage of imipramine (IMI) for nocturnal enuresis, were evaluated."( Steady-state serum concentrations of imipramine, its main metabolites and clinical response in primary enuresis.
Benetello, P; Bonin, P; Furlanut, M; Montanari, G; Pellegrino, PA; Schiaulini, P,
)
0.13
"The aim of the present study was to characterize the kinetic behavior of imipramine (IMI) and desipramine in enuretic children and to evaluate the performance of different methods for dosage prediction based on individual and/or population data."( Prediction of imipramine serum levels in enuretic children by a Bayesian method: comparison with two other conventional dosing methods.
Amador, D; Domínguez-Gil Hurlé, A; Fernández de Gatta, MM; García, MJ; Gutiérrez, JR; Rey, F; Tamayo, M, 1989
)
0.5
" S1 served as a control and at S2-4 oxotremorine dose-response curves were taken expressing the dose-related inhibition of the evoked release of [3H]norepinephrine as percentage of the control."( Antagonism by tricyclic antidepressants of the muscarinic receptors located on the adrenergic nerve endings in rabbit heart atrium.
Perel, JM; Somogyi, GT, 1989
)
0.28
" The study shows that it is possible to obtain a good estimation of individual dosage needs from one or more serum concentrations obtained at steady state."( Predictive techniques applied to imipramine therapeutic drug monitoring.
Domínguez-Gil, A; Fernandez de Gatta, MM; Garcia, MJ; Montojo, C; Ramón Gutierrez, J; Rey, F; Tamayo, M, 1989
)
0.28
" This is most likely due to the saturation within therapeutic dosage range of the subspecies of cytochrome P-450 responsible for hydroxylation of DMT."( Nonlinear kinetics of trimipramine in depressed patients.
Musa, MN, 1989
)
0.28
" Complete norepinephrine dose-response curves in 8 rats with chronic and 28 with early 1K1C hypertension, compared with appropriate normotensive control rats, showed unchanged thresholds and ED50 values."( The vascular Na+-K+ pump in experimental hypertension.
Overbeck, HW, 1987
)
0.27
" Twenty-four hours after a single dose of desipramine (10 mg/kg, intraperitoneally) the inhibitory dose-response curves to either UK 14 304 or desipramine itself did not differ significantly from those seen in control animals, whereas both were displaced significantly to the right after 15 days pretreatment with desipramine."( Effects of desipramine on stimulation-induced contractions of the vas deferens of rats pretreated either chronically with desipramine or acutely with idazoxan.
Doxey, JC; Roach, AG; Samuel, J, 1985
)
0.92
" No significant correlation was found between the dosage and the serum concentration of imipramine or desipramine."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.49
" Our study indicates that the discontinuation of diazepam, even when given in moderate dosage over a relatively short period of time, may cause withdrawal reactions in combined antidepressant/diazepam treatment."( Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients.
Feet, PO; Larsen, S; Lillevold, PE; Robak, OH, 1988
)
0.27
" Analysis of the total tricyclic concentration and the parent: desmethylated ratio revealed that those subjects in a depressive recurrence previously had had a lower imipramine: desipramine ratio (despite matched dosing and nonsignificant total plasma concentrations) than nonrecurrents."( Imipramine metabolism in recurrent depressive episodes.
Garvey, M; Tollefson, G; Tuason, VB; Valentine, R,
)
0.32
" If comparable dosage is administered, nonlinear increases in DMI levels result in lower OH-DMI/DMI ratios similar to those in younger patients."( Hydroxydesipramine in the elderly.
Atillasoy, E; Jatlow, PI; Mazure, C; Nelson, JC, 1988
)
0.73
"We describe the relationship of 2-hydroxydesipramine (OH-DMI) plasma levels and response in a prospective DMI study in which dosage was rapidly adjusted to achieve a relatively uniform DMI plasma level."( Antidepressant activity of 2-hydroxydesipramine.
Jatlow, PI; Mazure, C; Nelson, JC, 1988
)
0.82
" Severe toxicity usually occurs at supratherapeutic plasma levels and might be prevented by tailoring the dosage according to the individual's drug hydroxylating capacity."( Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
Bertilsson, L; Sjöqvist, F, 1986
)
0.27
" Following increases in dosage sufficient to raise DMI levels to greater than 150 ng/ml, four nonresponders improved dramatically."( Desipramine in agoraphobia with panic attacks: an open, fixed-dose study.
Lydiard, RB, 1987
)
1.72
" Plasma level determinations were measured 24 hours after a single dose of DMI 50 mg, and then at weekly intervals thereafter while receiving once daily bedtime dosing with DMI 150 mg or 200 mg."( Possible nonlinear pharmacokinetics of desipramine after once daily dosing.
Amsterdam, JD; Brunswick, DJ; Potter, L; Rickels, K, 1986
)
0.54
"1-30 mg/kg) elicited yawning that began 15-20 min after injection and lasted for 60 min, and the dose-response curve showed a bell-shaped form."( Desipramine induces yawning behaviour in rats.
Czyrak, A; Klimek, V; Mogilnicka, E; Wedzony, K, 1986
)
1.71
" Further fixed dosage studies are necessary to confirm these initial results."( Desipramine plasma concentration and therapeutic response in elderly depressives: a naturalistic pilot study.
Kutcher, SP; Reed, K; Shulman, KI, 1986
)
1.71
" In each patient, tinnitus subsided spontaneously within 2-4 weeks of onset without any specific treatment, even though the daily dosage of imipramine and the plasma tricyclic levels were constant or increased."( Imipramine and tinnitus.
Greden, JF; Grunhaus, L; Tandon, R, 1987
)
0.27
" Increasing the [Mg2+] in the external solution resulted in a right shift of both the [K+]o and the [Ca2+]o dose-response curves, consistent with actions of Mg2+ on screening surface membrane charges and blocking voltage-dependent Ca2+ channels."( Rapid release of [3H]dopamine from median eminence and striatal synaptosomes.
Gregerson, KA; Selmanoff, M, 1987
)
0.27
" During a control period, the dogs received bolus injections of epinephrine, norepinephrine, and levonordefrin sufficient to construct log-linear dose-response curves for each agent."( Drug interactions and vasoconstrictors used in local anesthetic solutions.
Duffin, SR; Hunt, LM; Yagiela, JA, 1985
)
0.27
"A low dosage of the specific MAO-A inhibitor clorgyline (5-10 mg/day) was administered chronically to 10 depressed patients."( The effect of clorgyline on noradrenergic function.
Hauger, RL; Lesieur, P; Linnoila, M; Potter, WZ; Ross, RJ; Rudorfer, MV; Scheinin, M; Siever, LJ, 1985
)
0.27
" Following a series of controlled dosage decreases, from 400 to 50 mg/day, the patient's steady state serum concentrations fit a nonlinear pharmacokinetic model."( Nonlinear desipramine pharmacokinetics: a case study.
Bishop, DS; Dugas, JE, 1985
)
0.67
" Based on amino acid patterns and serum drug levels only half of the patients received an optimal therapy on the applied schematic dosage schedule."( Biochemical and diagnostic classification and serum drug levels: relation to antidepressive effect of imipramine.
Elley, J; Krautwald, O; Larsen, OB; Møller, SE; Ortmann, J; Reisby, N, 1985
)
0.27
" It seems that administration of IMI with drinking water may be recommended as a reliable and convenient dosage schedule in experiments which need prolonged treatment with IMI."( Chronic dosage of imipramine in animal experiment: concentrations of imipramine and desipramine in the rat brain after various modes of dosage.
Danek, L; Daniel, W; Melzacka, M; Rurak, A; Vetulani, J,
)
0.36
"3 A second cannabis extract (II) with a different ratio of cannabinoids (also administered in dosage equivalent to 10 mg Delta(9)-THC/kg) failed to affect pentobarbitone anaesthesia in mice."( Interaction of cannabis and general anaesthetic agents in mice.
Chesher, GB; Jackson, DM; Starmer, GA, 1974
)
0.25
" The difference in sensitivity was greater in the lower than the upper parts of the dose-response curves."( Differences in sensitivity to vasoconstrictor drugs within the wall of the sheep carotid artery.
Graham, JM; Keatinge, WR, 1972
)
0.25
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
Schechter, MD, 1980
)
0.26
"The sensitivity of neurones in the cingulate cortex of the rat to iontophoretically applied substance P (SP) was tested one hour after a single dose of various antidepressant drugs and also 1 day following the termination of a chronic dosing schedule (14 once daily injections) of the same agents."( An increase in sensitivity of rat cingulate cortical neurones to substance P occurs following withdrawal of chronic administration of antidepressant drugs.
Jones, RS; Olpe, HR, 1984
)
0.27
" The mean maintenance dosage of trazodone was 300 mg (range 200-350 mg) and of imipramine 160 mg (range 150-175 mg)."( A double blind comparison of the efficacy and safety of trazodone and imipramine in endogenous depression.
Al-Yassiri, MM; Ankier, SI; Bridges, PK, 1983
)
0.27
"5 In rats with a sustained tachycardia (100 beats/min produced by electrical stimulation of the spinal cord) both mianserin and phentolamine, in contrast to desipramine, shifted the clonidine heart rate dose-response curve to the right."( Comparison of mianserin with desipramine, maprotiline and phentolamine on cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors and noradrenaline reuptake in pithed normotensive rats.
Cavero, I; Gomeni, R; Lefèvre-Borg, F; Roach, AG, 1980
)
0.75
" Dose-response curves were constructed using the cumulative dose-response technique (Frankhuyzen and Mulder, 1981)."( Pharmacological characterization of presynaptic alpha-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat.
Frankhuyzen, AL; Mulder, AH, 1982
)
0.26
" Future studies should control for severity of illness in assessing dose-response relationships."( Relationship of desipramine plasma levels to therapeutic response: a critical reappraisal of the data.
Friedel, RO, 1984
)
0.61
" The metabolite/parent ratios and the disposition of the individual metabolites confirm findings that chronic dosing results in only limited accumulation of hydroxy metabolites."( The analysis and disposition of imipramine and its active metabolites in man.
DeVane, CL; Jusko, WJ; Sutfin, TA, 1984
)
0.27
"It is important to understand both the kinetic and the dynamic implications of dosing TCAs and BZs in the elderly, for whom these drugs are frequently prescribed."( Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics.
Cutler, NR; Narang, PK, 1984
)
0.27
" When DMI dosage was raised after an initial steady state had been reached, the rise in plasma DMI level was proportionately greater than the increase in dosage, suggesting saturation of DMI elimination pathways."( The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
Cooke, RG; Persad, E; Reed, KL; Stancer, HC; Warsh, JJ, 1984
)
0.57
" With respect to both dosage and time, striatal DA was most sensitive to the effects of TBZ while hypothalamic NE was least affected."( Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.
Pettibone, DJ; Pflueger, AB; Totaro, JA, 1984
)
0.27
" Dosage regimens were adjusted individually to obtain a favorable response with regard to the frequency of enuresis and to the possible occurrence of side effects."( Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children.
Acosta, A; de Gatta, MF; Dominguez-Gil, A; García, MJ; Gutierrez, JR; Rey, F, 1984
)
0.53
" This finding may be related to the relatively low drug concentrations in this group of patients, a high placebo response rate, or noncompliance with the prescribed dosage regimen."( Concentrations of imipramine and its metabolites during enuresis therapy.
DeVane, CL; Sawyer, WP; Walker, RD; Wilson, JA, 1984
)
0.27
" Neither binodaline nor the desmethyl derivative was found to influence cerebral levels of NA, 5-HT and DA following acute dosing in rats."( Influence of the antidepressant binodaline on biogenic amine uptake and brain levels in the rat.
Benfield, DP; Luscombe, DK, 1983
)
0.27
"In order to better define the role of pharmacokinetic variation in reported cross-ethnic differences in dosing patterns of some psychoactive drugs, single dose kinetics of the tricyclic antidepressant desipramine (DMI) were studied in 14 Chinese and 16 Caucasian healthy volunteers."( Desipramine pharmacokinetics in Chinese and Caucasian volunteers.
Chang, WH; Lane, EA; Potter, WZ; Rudorfer, MV; Zhang, MD, 1984
)
1.9
" These data suggest that, as has been shown for other psychotropic drugs, single blood measures at 24 h post ingestion of 75 mg DMI can be used to predict optimal dosage in individual patients."( Prediction of steady state plasma and saliva levels of desmethylimipramine using a single dose, single time point procedure.
Bark, N; Cooper, TB; Simpson, GM, 1981
)
0.26
" Following completion of the dose-response determination for the effect of desipramine or water intake, rats were divided into three groups for repeated administration."( The effect of repeated desipramine administration on water intake in rats.
O'Donnell, JM; Rider, DP; Seiden, LS; Somani, S, 1982
)
0.81
" After long-term low doses of the drug (mean daily dosage 67."( Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure.
Blombery, P; Calil, HM; Kitanaka, I; Kopin, IJ; Linnoila, M; Potter, WZ; Ross, RJ; Zavadil, AP, 1983
)
0.27
" Administration of chlorimipramine in clinical dosage caused a complete disappearance of the 3H-mepyramine affinity for its receptor in the occipital cortex."( 3H-mepyramine binding in various regions of rat brain following chronic treatment with different classes of antidepressant drugs.
Dupont, A; Merand, Y; Savard, P, 1982
)
0.26
" The single dose clearance technique yielded a precise criterion for quantitating early compliance with and adjusting drug dosing regimens."( Estimating steady state desipramine levels in noninstitutionalized elderly patients using single dose disposition parameters.
Alderson, LM; Antal, EJ; Chapron, DJ; Kramer, PA; Lawson, IR, 1982
)
0.57
"Two schedules of imipramine (IM) administration were compared, a single intraperitoneal dose (10 mg/kg) (I) and chronic oral dosage (10 mg/kg twice a day for 14 days) (II)."( Different pharmacokinetic and pharmacological effects following acute and chronic treatment with imipramine.
Daniel, W; Maj, J; Melzacka, M; Mogilnicka, E, 1982
)
0.26
" Ten initial nonresponders were converted to responders when dosage increase raised desipramine plasma concentration to 125 ng/mL or above."( Desipramine plasma concentration and antidepressant response.
Bowers, MB; Jatlow, P; Nelson, JC; Quinlan, DM, 1982
)
1.93
" Chronic but not acute administration of DMI potentiated the locomotor response to d-amphetamine within a narrow dosage range."( Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine.
Fibiger, HC; Spyraki, C, 1981
)
0.47
"Twenty-six symptomatic subjects who met research diagnostic criteria for major affective disorder and were free of cardiovascular disease were treated for 3 wk with a fixed dosage schedule of desipramine (DMI) to a maximum of 200 mg/day."( Electrocardiogram changes and plasma desipramine levels during treatment of depression.
Bielski, R; Bloom, V; Friedel, RO; Veith, RC, 1980
)
0.72
" Objective measurements of salivation and pulse rate and subjective ratings of mouth dryness and palpitations were made before and during treatment with desipramine at a final daily dosage of 150 mg."( Anticholinergic effects and plasma desipramine levels.
Rudorfer, MV; Young, RC, 1980
)
0.74
"6-mg/kg doses of GBR 12909 produced downward shifts in the dose-response curves for cocaine (0."( Effects of monoamine reuptake inhibitors on cocaine self-administration in rats.
Tella, SR, 1995
)
0.29
" In the present report, we confirm and extend our original results to include dose-response data and the effect of selective uptake inhibition on the levels of monoamine neurotransmitters in various regions of the mouse brain following treatment with 2'-NH2-MPTP."( Fluoxetine and desipramine selectively attenuate 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine.
Andrews, AM; Murphy, DL, 1993
)
0.64
"5 mg/kg), each dosage being given for 2 weeks."( Plasma levels and efficacy of imipramine treatment for enuresis.
Fritz, GK; Rockney, RM; Yeung, AS, 1994
)
0.29
" In many instances, a knowledge of the drug metabolism status of a patient can be helpful in the selection of a drug and its dosage regimen, and in the prediction of possible drug/drug interactions when two or more drugs have to be administered concomitantly."( Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
Coutts, RT, 1994
)
0.29
" Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.86
" Addition of fluvoxamine to patients on a stable desipramine dosage regimen resulted in a slight, but statistically not significant, increase in desipramine plasma concentrations."( Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
Avenoso, A; Campo, GM; Caputi, AP; Pollicino, AM; Spina, E, 1993
)
0.77
" These findings indicate that, at the dosage tested, fluvoxamine markedly inhibits the demethylation of imipramine without affecting significantly the CYP2D6-mediated hydroxylation of desipramine."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.72
"The antinociceptive effect of three antidepressants with different postulated modes of action, 75 mg desipramine, 225 mg fluvoxamine, and 450 mg moclobemide, was evaluated after single oral dosing in a randomized, double-blind, placebo-controlled crossover study in 10 healthy volunteers."( Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers.
Coquoz, D; Dayer, P; Porchet, HC, 1993
)
0.79
" A dose-response relationship was evident; animals given the highest dose of desipramine-specific Fab showed the greatest improvement."( Ovine desipramine antibody fragments reverse desipramine cardiovascular toxicity in the rat.
Dart, RC; Egen, NB; Garcia, RA; Sidki, A; Sullivan, JB, 1996
)
1
" Blood level:dose ratios and dose-response relationships for cyclosporine were virtually identical in all three groups before and during treatment."( Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients.
Fairbanks, LA; Fawzy, FI; Skotzko, CE; Strouse, TB,
)
0.13
" Comparative results indicated that dosage of any adjunct therapy was associated with days in treatment and standard treatment sessions attended, and that standard treatment sessions attended was associated with negative urinalysis results at follow-up."( Effectiveness of adjunct therapies in crack cocaine treatment.
Montoya, ID; Nelson, R; Richard, AJ; Spence, RT,
)
0.13
"1-fold leftward shift in the dose-response curve."( Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
Gergen, KA; Kastin, AJ; Paul, D; Zadina, JE, 1996
)
0.29
" Neither the prolactin nor the ACTH response was augmented significantly in the animals exposed prenatally to either nicotine dosage regimen, although there was a strong trend for the augmentation to occur in the low-dose nicotine exposed animals."( Exposure to threshold doses of nicotine in utero: III. Augmentation of the prolactin and ACTH response to 8-OH DPAT by desipramine treatment is compromised in adult male offspring.
Acosta, S; Au, D; Lutchmansingh, P; McCracken, JT; McGeoy, S; Poland, RE; Que, M, 1996
)
0.5
" For all but one patient, daily dosage at bedtime was constant for the final 4 weeks, with a mean (S."( 2-Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response?
Cooper, TB; Johnson, MH; Nelson, LD; Stern, SL; Suckow, RF, 1996
)
0.71
"After CYP2D6 phenotype determination with dextromethorphan, 31 patients were treated with oral DMI at a dosage of 100 mg per day for 3 weeks."( Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
Avenoso, A; Campo, GM; Caputi, AP; Gitto, C; Perucca, E; Spina, E, 1997
)
0.59
" The two patients with the poor metabolizer phenotype showed the highest plasma concentrations of DMI and complained of severe adverse effects, requiring dosage reduction."( Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
Avenoso, A; Campo, GM; Caputi, AP; Gitto, C; Perucca, E; Spina, E, 1997
)
0.59
" No gender difference in HPA axis activation was observed in a dose-response study of cocaine-induced HPA activation in 10 day old rats."( Gender difference in cocaine-induced HPA axis activation.
Francis, R; Kuhn, C, 1997
)
0.3
" In these rats, the power values were less than three times those before the dosing of PTZ or beta-CCM."( [A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists].
Hatsuda, S; Matsubara, M; Miura, K; Murakami, H; Nakazawa, K; Ohara, M; Sugita, S; Suzuki, S; Terashima, M, 1997
)
0.3
" Input files require estimates of binding coefficients, first- and/or second-order metabolism constants, level of interaction between the two chemicals, and dosing information."( A computer model and program for xenobiotic disposition during pregnancy.
Luecke, RH; Pearce, BA; Wosilait, WD; Young, JF, 1997
)
0.3
" Amitriptyline inhibited the GAT1 and GAT3 at the reasonable dosage for clinical administration."( Effects of tricyclic and tetracyclic antidepressants on the three subtypes of GABA transporter.
Nakashita, M; Saito, N; Sakai, N; Sasaki, K, 1997
)
0.3
" However, rabbit platelets incubated with desipramine showed a biphasic dose-response change in PKC activity in vitro."( Effect of the tricyclic antidepressant desipramine on protein kinase C in rat brain and rabbit platelets in vitro.
Morishita, S; Watanabe, S, 1997
)
0.83
" We found that each AME-DMI infusion, between dosages of 1 mM and 10 mM, stimulated a GnRH pulse, and that the size of these GnRH pulses were proportional to the dosage of DMI."( Possible involvement of norepinephrine transporter activity in the pulsatility of hypothalamic gonadotropin-releasing hormone release: influence of the gonad.
Cowles, A; Hess, DL; Lee, CJ; Pau, KY; Spies, HG; Yang, SP, 1998
)
0.3
" In the present study, a K+ dose-response curve was obtained for the release of both [3H]-DA and endogenous DA from striatal tissue, in the absence and presence of catecholamine uptake blockers."( Mazindol, nomifensine and desmethylimipramine inhibit potassium-induced release of dopamine: effect of stimulus strength.
Dembiec-Cohen, D, 1998
)
0.3
" Subjects were then treated with DMI, titrated to an average DMI dosage of 3 mg/kg, and underwent repeated exercise testing."( Cardiovascular effects of desipramine in children and adults during exercise testing.
Bigger, JT; Bilich, K; Giardina, EG; Greenhill, LL; Sloan, RP; Walsh, BT; Waslick, BD, 1999
)
0.6
" In each session, dose-response curves to both locally infused noradrenaline acid tartrate (0."( Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein.
Abdelmawla, AH; Bradshaw, CM; Langley, RW; Szabadi, E, 1999
)
0.57
" The flexible dosage range was 50 to 150 mg/d."( Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.
Freeman, EW; Polansky, M; Rickels, K; Sondheimer, SJ, 1999
)
0.3
" Thirty-two reports (29 studies) evaluated adverse effects of drug therapy; many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments."( Treatment of attention-deficit/hyperactivity disorder.
Boyle, M; Cunningham, C; Jadad, AR; Kim, M; Schachar, R, 1999
)
0.3
" The combined therapies were most effective in patients who were more severely depressed, particularly when desipramine was at or above recommended stable dosage levels."( Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression.
Coon, DW; Gallagher-Thompson, D; Koin, D; Sommer, BR; Thompson, LW, 2001
)
0.88
" However, it is also known to accumulate in various tissues up to several times higher after standard oral dosing and we now have evidence from both in vivo and in vitro experiments with spontaneously hypertensive rats (SHR) that millimolar levels stimulate release of norepinephrine (NE) from vascular sympathetic nerve endings (SNEs)."( A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats.
Lee, JM; Peuler, JD, 2001
)
0.31
" In addition, dose-response curves for the inhibitory LC activity of clonidine showed a shift to the right in deprived animals indicating a subsensitivity of alpha2-adrenergic autoreceptors."( Increased neuronal activity in locus coeruleus from adult rats undernourished at perinatal age: its reversal by desipramine.
Cuadra, GR; Nasif, FJ; Orsingher, OA; Ramírez, OA, 2001
)
0.52
" Dose-response curves were constructed for seven agonists in each of the brain regions."( Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions.
Cao, J; Collins, AC; Grady, SR; Marks, MJ; McIntosh, JM; Murphy, KL, 2002
)
0.31
" TYR PD30 increased significantly with desipramine dosing (p<0."( Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Bieck, PR; Bymaster, FP; Chalon, SA; Granier, LA; Hirth, C; Joliat, MJ; Potter, WZ; Vandenhende, FR, 2003
)
0.59
" Dose-response curves were established for the noradrenaline-induced (10(-12) to 10(-7) mol/kg) increase of diastolic blood pressure in pithed rats treated with tubocurarine, propranolol, and atropine."( Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation.
Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A, 2004
)
0.32
" In this study, the effects of two dosing regimens of duloxetine on sleep electroencephalography (EEG) were investigated at steady-state plasma concentrations in young, healthy, male subjects."( Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects.
Chalon, S; Granier, LA; Lainey, E; Pereira, A; Staner, L; Vandenhende, F; Watkin, JG, 2005
)
0.6
" Mechanisms of desipramine toxicity and its dosage recommendations are discussed."( Excess fatality from desipramine and dosage recommendations.
Amitai, Y; Frischer, H, 2004
)
1
" Within psychiatry, when using higher dosage of TCAs, plasma levels can be used to adjust daily dosage to optimize a treatment response."( Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage.
Bangdiwala, SI; Dalton, CB; Diamant, NE; Drossman, DA; Halpert, A; Hu, Y; Morris, CB; Toner, BB; Whitehead, WE, 2005
)
0.33
" Following recovery, the animals were orally dosed at light onset with either desipramine (20 mg/kg), fluoxetine (10 mg/kg), citalopram (10 or 40 mg/kg) or vehicle in a cross-over design."( Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats.
Hutson, PH; Ivarsson, M; Paterson, LM, 2005
)
0.56
" In the present study, we performed a full dose-response study of the effect of systemic reboxetine and desipramine on DA and NA in dialysates from the parietal and occipital cortices."( Differential alpha-mediated inhibition of dopamine and noradrenaline release in the parietal and occipital cortex following noradrenaline transporter blockade.
Cacciapaglia, F; Di Chiara, G; Frau, R; Valentini, V, 2006
)
0.55
"The present study has addressed the question of what is more important for the occurrence of adaptive changes observed in the organism treated with antidepressant drugs: a daily dosing of the drug or the period of time necessary for the plastic events to develop."( Delayed effects of antidepressant drugs in rats.
Dziedzicka-Wasylewska, M; Faron-Górecka, A; Kuśmider, M, 2006
)
0.33
" They received desipramine for 6 weeks in order to simulate the length of time and dosing used previously to obtain an IR-1 down-regulation and a therapeutic response in depressed patients."( Platelet imidazoline receptors as state marker of depressive symptomatology.
Baker, R; Halaris, A; Piletz, J, 2008
)
0.7
" Thus, different dosing regiments are needed to achieve similar brain drug levels in juvenile and adult rats."( Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.
Burke, WJ; Bylund, DB; Deupree, JD; Kozisek, ME, 2007
)
0.58
" The contradiction between our results and those of several previous studies may be due to the fixed plasma level dosing of imipramine refraining from concurrent psychotropic medication or limiting our patient sample to patients with mood-congruent psychotic features."( Efficacy of imipramine in psychotic versus nonpsychotic depression.
Birkenhager, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2008
)
0.35
" Overall, the dose-response and time-of-recovery relationships for altered NET expression matched those for production of antidepressant-like effects on behavior."( Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.
Baros, AM; Bondi, CO; Lapiz, MD; Morilak, DA; O'Donnell, JM; Zhang, HT; Zhao, Z, 2008
)
0.56
" Ketoconazole strongly inhibited CYP3A4-mediated terfenadine metabolism in vitro, and the method predicted 6- to 37-fold increase of terfenadine AUC by the concomitant dosing of ketoconazole, which reasonably well agreed with the observed 13- to 59-fold increase of AUC in clinical studies."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.35
" The CYP2D6 substrate desipramine (50 mg) was administered alone on day 1 and coadministered on day 6 of dosing with either desvenlafaxine or paroxetine."( The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Ahmed, S; Fatato, P; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, RD; Shenouda, M, 2009
)
0.88
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain."( Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
Adedoyin, A; Bray, JA; Deecher, DC; Fensome, A; Goldberg, JA; Harrison, J; Leventhal, L; Mann, C; Mark, L; Nogle, L; O'Neill, DJ; Spangler, TB; Sullivan, NR; Terefenko, EA; Trybulski, EJ; Uveges, AJ; Vu, A; Whiteside, GT; Zhang, P, 2011
)
0.37
" Dose-response assessments demonstrated that rats housed in EE showed reduced sensitivity to the behavioural effects of DZP and DMI but increased sensitivity to the locomotor-enhancing effects of AMP compared to SC and IC; while IC animals exhibited the clearest dose-response effects to increasing doses of DMI."( The effects of isolated and enriched housing conditions on baseline and drug-induced behavioural responses in the male rat.
Kelly, JP; Simpson, J, 2012
)
0.38
"CD-1 mice were dosed with Bacille Calmette-Guérin (BCG) and measures of body weight, locomotor activity, and immobility in the tail suspension test (TST) were made."( A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.
Clark, JA; Klee, N; Nizami, M; Platt, B; Schulenberg, J, 2013
)
0.39
" These include biological factors, such as strain, age, body weight, gender and individual differences between animals; influence of preconditioning before the FST: handling, social isolation or enriched environment, food manipulations, various kinds of stress, endocrine manipulations and surgery; schedule and routes of treatment, dosage and type of the drugs as well as experimental design and laboratory environmental effects."( Factors influencing behavior in the forced swim test.
Bogdanova, OV; D'Anci, KE; Kanekar, S; Renshaw, PF, 2013
)
0.39
" DMI and fluoxetine produced an antidepressant-like effect in YA and MA animals, although in the latter group, a shift to the right in the dose-response curve was found for DMI."( Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test.
Fernández-Guasti, A; Martínez-Mota, L; Olivares-Nazario, M, 2016
)
0.68
" Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted."( Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
Gao, ZB; Gunosewoyo, H; Liu, T; Pang, T; Shi, JJ; Shi, M; Sun, H; Tang, J; Xu, YZ; Yang, F; Yu, LF; Zhang, W; Zheng, YM, 2016
)
0.43
" The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations."( The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Callegari, E; Nguyen, HQ; Obach, RS, 2016
)
0.87
" The model also accounts for the extended time to reach maximum concentration after oral dosing due to enterocyte trapping."( Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study.
Lukacova, V; Samant, TS; Schmidt, S, 2017
)
0.66
" In one study, tics limited further dosage increases of methylphenidate."( Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland, ST; Pringsheim, T; Steeves, TD, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitorAn EC 3.1.4.* (phosphoric diester hydrolase) inhibitor that interferes with the action of sphingomyelin phosphodiesterase (EC 3.1.4.12).
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dibenzoazepine
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Imipramine Action Pathway3521
Desipramine Action Pathway3217
Imipramine Metabolism Pathway612
Desipramine Metabolism Pathway38

Protein Targets (89)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency8.43680.100020.879379.4328AID588456
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency16.93300.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency5.35470.00108.379861.1304AID1645840
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency33.58750.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency14.55000.00207.533739.8107AID891
D(1A) dopamine receptorHomo sapiens (human)Potency6.52780.02245.944922.3872AID488982; AID488983
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID2669
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.00790.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency16.48160.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.40540.00378.618923.2809AID2667; AID2668
gemininHomo sapiens (human)Potency14.31940.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.27510.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency16.27100.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency1.56730.00106.000935.4813AID943; AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency14.68920.00378.108123.2809AID2667
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency14.12540.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency16.27101.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)Ki16.00000.10001.52203.4000AID681171
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)32.99000.21005.553710.0000AID1442001; AID386625
Solute carrier family 22 member 1 Homo sapiens (human)Ki5.36000.55004.26507.4600AID681146
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier family 22 member 3Homo sapiens (human)Ki14.00000.12000.12000.1200AID681584
Solute carrier family 22 member 3Rattus norvegicus (Norway rat)IC50 (µMol)68.00004.90006.65008.4000AID682029
Bile salt export pumpHomo sapiens (human)IC50 (µMol)139.46670.11007.190310.0000AID1443980; AID1449628; AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)Ki0.16000.00162.12129.0000AID5444
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00040.629810.0000AID6418
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00030.00001.44217.3470AID36031
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)Ki0.00050.00050.09140.4900AID64525
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)27.84970.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki22.81660.00042.03378.6606AID625171
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.35000.00040.908610.0000AID6418
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00340.00021.874210.0000AID441348
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00030.00001.23808.1590AID36031
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00030.00001.47257.8980AID36031
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.35000.00031.38338.4000AID6418
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.00310.00081.541620.0000AID1824591; AID339393; AID351894; AID352215; AID378466; AID387487; AID410149; AID431881; AID441348; AID446936; AID459949; AID459950; AID481497; AID619830; AID751640; AID773432
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.04050.00031.465610.0000AID1063770; AID1626219; AID1799301; AID1831035; AID284828; AID338159; AID339392; AID431485; AID431882; AID452389; AID483451; AID483452; AID619831; AID751640
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)7.80000.00070.97749.7000AID181678
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki7.00000.00030.37088.1600AID238633; AID65494
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.08030.00000.385510.0000AID1799301; AID5444
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00051.48357.8000AID6418
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00311.73607.8000AID6418
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.79627.8000AID6418
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00040.615610.0000AID6418
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.50894.6000AID6418
Histamine H1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00080.00000.32271.2589AID87513
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.19610.00010.86458.7096AID289407; AID289408; AID351887; AID729797
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.02000.00000.70488.1930AID537571
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)20.00000.00030.81978.4900AID181681
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.16300.00000.705610.0000AID204709
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.42824.6000AID6418
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.35984.6000AID6418
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.35984.6000AID6418
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.35000.00021.13514.6000AID6418
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00030.00001.819410.0000AID36031
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)3.80000.00402.15557.2000AID87880
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)56.80002.03005.53139.9000AID386625
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)11.00000.04004.113710.0000AID1850268
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)41.60000.00071.841946.0000AID289403; AID289404; AID289405; AID289406; AID351888
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.75040.00021.11158.0280AID64512; AID64525
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)4.70930.00091.901410.0000AID1207212; AID161281; AID243151; AID397743; AID408340; AID576612; AID625171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki22.81660.00211.840710.0000AID625171
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)1.52000.00033.64849.2000AID1207153
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)0.35000.00501.35524.6000AID6418
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)17.50000.18003.68578.8000AID681159
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki2.80000.13002.37856.9000AID681157
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)27.84970.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki22.81660.08582.95428.6606AID625171
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.35000.00041.17424.6000AID6418
Histamine H3 receptorRattus norvegicus (Norway rat)Ki5.00000.00010.29638.5110AID537544
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)10.00001.00004.446710.0000AID681158
TransporterRattus norvegicus (Norway rat)IC50 (µMol)10.65000.00081.95628.8000AID181678; AID181680
TransporterRattus norvegicus (Norway rat)Ki0.00740.00010.866710.0000AID145400; AID238634
Histamine H3 receptorHomo sapiens (human)Ki5.00000.00010.33998.5110AID537545
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd851.13800.08933.31358.0000AID327170
Sodium-dependent noradrenaline transporter Homo sapiens (human)Kd0.00080.00080.25331.0600AID537546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.04540.00010.40364.8000AID88008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (318)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (146)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (75)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (497)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID681703TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Desipramine: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID173375In vivo antagonism of histamine-induced ACTH release in the rat at 10 mg/kg (ip).1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID619830Inhibition of human NET expressed in MDCK-Net6 cells assessed as inhibition of norepinephrine uptake2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID578396Antidepressant activity in mouse assessed as reduction of immobility duration pretreated for 30 mins at 100 mg/kg, po by tail suspension test2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.
AID6418Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1129167Permeability of the compound by PAMPA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID680303TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Desipramine: 20 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID681158TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID357489Inhibition of [3H]NE uptake at human NET E382A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID195552Inhibition of neuronal uptake of Noradrenaline in rat brain homogenate1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1319307Permeability of the compound in PBS/EtOH (7:3) buffer measured after 10 hrs by PAMPA assay2016Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1319973Permeability of the compound by PAMPA assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID221731Ability to kill 50% of the animals after 24h, when administered perorally1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID410149Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID537571Inhibition of SERT2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID1071344Permeability of the compound by BBB-PAMPA2014European journal of medicinal chemistry, Feb-12, Volume: 731,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID109916Antidepressant activity was assessed from the ability to antagonize reserpine-induced palpebral ptosis on peroral administration in mice; Value ranges from (1.3-3.4).1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID1421886Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID441348Inhibition of human NET expressed in MDCK-Net6 cells2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.
AID387487Inhibition of norepinephrine uptake at human NET expressed in MDCK cells2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID129181Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after ip administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1319976Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1207243Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1135984Potentiation of 5-HTP-induced head twitches in ip dosed NMRI albino mouse administered 1 hr prior to 5-HTP challenge1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1131083Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 5. Conformationally mobile analogues derived by furan ring opening.
AID159539Tested for in vitro reuptake inhibition of [3H]norepinephrine in pig occipital synaptosomes.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID1831035Displacement of [3H]-Nisoxetine from human NET expressed in HEK cell membrane assessed as inhibition constant by radioligand binding assay2021Bioorganic & medicinal chemistry, 12-01, Volume: 51C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID357495Inhibition of [3H]NE uptake at human NET T474H mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1134043Antitetrabenazine activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine-induced ptosis challenged with tetrabenazine after 30 mins later and after another 30 mins of drug treatment1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen.
AID1169140Retention time of the compound by EPSA supercritical fluid chromatography2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID5444Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID156204Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1480942Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1824591Inhibition of norepinephrine transporter (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
AID34291Compound was evaluated for in vitro inhibition of histamine activated adenylate cyclase in guinea pig cerebral cortex1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID1207153Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID682029TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells1998The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.
AID1135982Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]5-HT accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID145400Ability to inhibit reuptake of norepinephrine ([3H]NE) at norepinephrine transporter of rat parietal/occipital region2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and pharmacological evaluation of (Z)-9-(heteroarylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes: thiophene analogues as potent norepinephrine transporter inhibitors.
AID1421885Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID127789In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID288190Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID87513Compound tested for its inhibitory activity against Histamine H1 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID639368Permeability of the compound by PAMPA assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID357481Inhibition of [3H]NE uptake at human NET E223Q mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1862044Effective permeability of the compound at pH 7.4 measured after 18 hrs by PAMPA-BBB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 692-Aminopyridines with a shortened amino sidechain as potent, selective, and highly permeable human neuronal nitric oxide synthase inhibitors.
AID351890Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum Dd2 infected human erythrocytes by SYBR green assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID26538log K was measured potentiometrically in Brij35 medium1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID338196Displacement of [3H]DMI from norepinephrine transporter assessed as specific binding relative to total binding1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID128147Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID659472Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
AID34293Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID26520Partition coefficient (logD) (HPLC)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID351888Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID729797Inhibition of human SERT expressed in HEK293-MSR cells by 5-HT uptake assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID181680Inhibition of norepinephrine reuptake in rat whole brains minus cerebellar1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
AID397743Inhibition of human ERG channel2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID22345Therapeutic plasma levels for the compound was evaluated.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID180133Inhibition of uptake of tritiated serotonin (5-HT) into rat brain synaptosomes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID635079Permeability of the compound after 2.5 hrs by PAMPA-BBB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
AID427198Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1713986Effective permeability of the compound in PBS/ethanol buffer (9:1) at 25 ug/ml after 10 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID1636362Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 131.8 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1862043Effective permeability of compound in PBS buffer at pH 7.4 at 200 uM incubated for 17 hrs by PAMPA-BBB assay2022Bioorganic & medicinal chemistry, 09-01, Volume: 692-Aminopyridines with a shortened amino sidechain as potent, selective, and highly permeable human neuronal nitric oxide synthase inhibitors.
AID483452Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
AID212885Compound dose that causes lethality (acute toxicity) was determined by administering perorally in mice.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID1626219Displacement of [3H]nisoxetine from human NET expressed in HEK293 cells measured after 30 mins2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID110072Ability to antagonise tetrabenazine (TBZ)-induced depression measured in mice for motor activity by subcutaneous administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID339393Inhibition of norepinephrine uptake at human norepinephrine transporter expressed in MDCK-Net6 cells2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID28928Intrinsic permeability of the compound2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID288186Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID181518Ability to inhibit the uptake of serotonin (5-HT) by crude synaptosomes from rat whole brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID1207636Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1831038Displacement of [3H]-Nisoxetine from human NET expressed in HEK cell membrane at 10 uM by radioligand binding assay relative to control2021Bioorganic & medicinal chemistry, 12-01, Volume: 51C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters.
AID178314Potentiation of head twitching induced by 5-HTP in pargyline-pretreated rats following i.p. administration.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Novel tetracyclic spiropiperidines. 3. 1-arylspiro[indoline-3,4'-piperidine]s as potential antidepressants.
AID681584TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID172545In vivo noradrenergic responsiveness in the rat pineal gland at 10 mg/kg (ip) (single treatment); No significant effect1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID289407Inhibition of [3H]serotonin uptake in human wild type SERT transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID357483Inhibition of [3H]NE uptake at human NET L232P mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID130112Compound was evaluated for its antagonistic effect on the Tetrabenazine-induced ptosis following intravenous administration1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID1183278Permeability of the compound by PAMPA2014European journal of medicinal chemistry, Sep-12, Volume: 84Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID357491Inhibition of [3H]NE uptake at human NET E393A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID196063Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID289409Inhibition of [3H]leucine transport activity of LeuT in proteoliposomes by scintillation proximity assay2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID679770TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Desipramine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1909448Permeability of the compound by PAMPA-BBB assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID23708Partition coefficient (logP)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID15708Plasma clearance for the compound was determined.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1693561Effective permeability of compound in PBS/EtOH buffer (7:3) at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
AID109910Antidepressant activity was assessed from the ability to antagonize reserpine-induced hypothermia on peroral administration in mice; Value ranges from 0.9-3.3.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID357474Inhibition of [3H]NE uptake at human NET N170E mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1230203Permeability of the compound using PDVF membrane after 2 hrs 45 mins by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID330664Effect on life span of Caenorhabditis elegans at 10 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID178456Antidepressant activity was measured by the potentiation of head twitching induced by 5-hydroxy-tryptophan in pargyline-pretreated rats after ip administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID130699In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1511118Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID177982Compound was screened in vivo for antidepressant activity by tryptamine seizure potentiation method in rat.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
(+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 1. Synthesis and evaluation of (+/-)-4,5-dihydro-2,3-dimethyl-4-phenyl-3H-1,3-benzodiazepine and analogues as potential antidepressant agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1370632Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
AID238633Inhibitory constant against reuptake of [3H]-DA at dopamine transporter of rat striatal membranes2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants.
AID179084Compound was tested for inhibition of uptake of [14C]5-HT (5-HT) into rat whole brain, in vitro.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
2,3,4,4a,5,9b-Hexahydro-1H-indeno[1,2-b]pyridines: potential antidepressants.
AID338159Displacement of [3H]DMI from norepinephrine transporter1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID537544Displacement of [3H]N-R-methylhistamine from rat H3 receptor2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1135981Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]NA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1384014Effective permeability of the compound dissolved in PBS at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID25866Protonation constant of the compound.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID177339In vivo for the inhibition of muricidal activity. The effective dose (intraperitoneally) required for the activity was determined in rat1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
(+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 1. Synthesis and evaluation of (+/-)-4,5-dihydro-2,3-dimethyl-4-phenyl-3H-1,3-benzodiazepine and analogues as potential antidepressant agents.
AID1207182Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1772562n-Octanol/PBS buffer distribution coefficient, logD of the compound at pH 7.42021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID459950Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID22538Half life period is estimated1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1713987Effective permeability of the compound at 25 ug/ml after 18 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID1135980Inhibition of 5-HT transporter in NMRI albino mouse brain assessed as [3H]5-HT accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1135983Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]DA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID181681Inhibition of serotonin reuptake in rat whole brains without cerebellum1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
AID28923Effective permeability measured with Caco-2 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1480849Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID343685Ratio of drug level in brain to blood in Wistar rat2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID179087Compound was tested for inhibition of uptake of [14C]norepinephrine (NE) into rat brain hypothalamus, in vitro.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
2,3,4,4a,5,9b-Hexahydro-1H-indeno[1,2-b]pyridines: potential antidepressants.
AID128144Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID178197Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID26518Partition coefficient (logD) (HPLC)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID459949Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1056993Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID289402Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID88008Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID1404015Permeability of the compound after 2.5 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID357477Inhibition of [3H]NE uptake at human NET H178N mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID223123Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID431881Inhibition of [3H]norepinephrine uptake at human NET expressed in MDCK-Net6 cells by scintillation counting2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID357479Inhibition of [3H]NE uptake at human NET N192D mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1367014Permeability of compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
AID186205Log (1/ED50) was measured as histamine releasing activity in rat mast cells; log(1/ED50*10e-3).1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID204709Ability to inhibit reuptake of serotonin ([3H]5-HT) at serotonin transporter of rat midbrian2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and pharmacological evaluation of (Z)-9-(heteroarylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes: thiophene analogues as potent norepinephrine transporter inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID289405Inhibition of [3H]dopamine uptake in human DAT I390V mutant transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID196059Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID681159TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID1161578Permeability of the compound by PAMPA-BBB assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID34292Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID65494Inhibitory constant towards reuptake of [125I]-12 from dopamine transporter in rat striatal membranes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents.
AID175362Concentration required to inhibit [3H]- NE(norepinephrine) uptake in to rat cortical synaptosomes1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1264455Permeability of the compound by high throughput PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID23961logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1651957Antidepressant activity in Swiss Webster (Harlan) mouse assessed as decrease in immobility time at 20 mg/kg, ip after 30 mins by forced swim test2020Journal of natural products, 04-24, Volume: 83, Issue:4
Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine Sponge
AID64512Compound was tested for inhibition of [3H]WIN-35428 binding to the human (DAT) dopamine transporter1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.
AID1850268Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay2022RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2
Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID222978Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID132666In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID339423Antinociceptive activity in CD1 mouse assessed as reduction in p-phenylquinone-induced abdominal constricitions at 30 mg/kg, sc after 60 mins relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID109908Amphetamine antagonistic activity on peroral administration in mice; Value ranges from (29.4-65.9)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID481497Inhibition of human NET transfected in MDCK-Net6 cells2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID682228TP_TRANSPORTER: inhibition of Guanidine uptake (Guanidine: 35 uM, Desipramine: 5000 uM) in OCT3-expressing HeLa cells1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.
AID483451Inhibition of human NET-mediated norepinephrine uptake in MDCK-Net6 cells2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
AID537546Inhibition of human NET2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID289403Inhibition of [3H]dopamine uptake in human wild type DAT transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID648667Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID29845Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID775111Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
AID431485Inhibition of [3H]norepinephrine reuptake at norepinephrine transporter2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID288193Flux ionization constant, pKa of the membrane permeability coefficient of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID357470Inhibition of [3H]NE uptake at human NET EL2 chimera mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID180132Inhibition of uptake of tritiated norepinephrine (NE) into rat brain synaptosomes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID339420Antidepressant activity in mouse assessed as decrease in immobility time at 8 mg/kg, ip2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID357487Inhibition of [3H]NE uptake at human NET D310A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID357482Inhibition of [3H]NE uptake at human NET H228D mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1636418Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 132.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID357499Inhibition of [3H]NE uptake at human NET P552D mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID1264447Permeability of the compound by PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1384013Effective permeability of the compound dissolved in PBS containing 1% F-127 at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID132665In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1623120Effective permeability of the compound by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID352215Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
AID357500Inhibition of [3H]NE uptake at human NET W556A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID431882Inhibition of [3H]nisoxetine binding to human NET expressed in MDCK-Net6 cells by plate scintillation counting2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
AID28926Effective permeability corrected for ionization2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID156202Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID729813Induction of apoptosis in human DG75 cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID87880Inhibitory activity against brain adenylate cyclase Histamine H2 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID130715In vivo inhibition of uptake of nor epinephrine in mouse heart; value ranges from 0.5-3.51985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID729821Reduction in cell viability of human MUTU-I cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID289408Inhibition of [3H]serotonin uptake in human SERT K490T mutant transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID26300log P values determined at pH 7.41999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID357471Inhibition of [3H]NE uptake at human wild type NET expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID183727Inhibitory activity of compound against ability of NE to enhance the inhibition produced by GABA after 1 i.p. injection of 10 mg/kg administered (acute treatment)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID357486Inhibition of [3H]NE uptake at human NET E304A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID129282Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after po administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID729819Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID357497Inhibition of [3H]NE uptake at human NET D546G mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID357472Inhibition of [3H]NE uptake at human NET E122A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID48901Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 2 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID729814Induction of apoptosis in human MUTU-I cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135986Acute toxicity in iv dosed NMRI albino mouse assessed as lethality up to 24 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1476986Effective permeability of compound at 200 uM after 18 hrs by PAMPA-BBB assay2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID130700In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID330661Effect on life span of Caenorhabditis elegans at 200 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID147591Compound was tested for its inhibitory activity against Noradrenaline receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID181517Ability to inhibit the uptake of norepinephrine (NE) by crude synaptosomes from rat whole brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID1476985Effective permeability of compound at 200 uM after 17 hrs by PAMPA-BBB assay2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID26396Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID288194Intrinsic artificial membrane permeability coefficient, log P0 of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID751705Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells at 10 uM after 3 hrs relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID378466Displacement of [125I]RTI-55 from human NET expressed in MDCK cell membrane2006Journal of natural products, Sep, Volume: 69, Issue:9
Antidepressant principles of the roots of Polygala tenuifolia.
AID181678Inhibition of the reuptake of dopamine in rat corpora striata.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
AID288187Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID681171TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1997DNA and cell biology, Jul, Volume: 16, Issue:7
Cloning and characterization of two human polyspecific organic cation transporters.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID339392Displacement of [3H]nisoxetine from human norepinephrine transporter expressed in MDCK-Net6 cells2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID729820Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID729812Induction of apoptosis in human HeLa cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID357480Inhibition of [3H]NE uptake at human NET G193S mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID159537Tested for in vitro reuptake inhibition of [3H]-5-hydroxy tryptamine in pig frontal synaptosomes.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID360444Displacement of [3H]RTI82 from DAT in rat striatal membrane2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID637605Permeability of the compound by PAMPA2012European journal of medicinal chemistry, Feb, Volume: 48A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
AID189474Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1357286Inhibition of mmLDL-stimulated acid sphingomyelinase in human PBMC lysates assessed as enzyme residual activity at 25 uM using 3H-sphingomyelin as substrate preincubated for 30 mins followed by mmLDL stimulation measured after 2 hrs by HPLC method2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID109922Pentylenetetrazole antagonistic activity on peroral administration in mice; Value ranges from (24.5-41.4)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID357484Inhibition of [3H]NE uptake at human NET Q234R mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID357478Inhibition of [3H]NE uptake at human NET K189H mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID223128Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID446936Inhibition of norepinephrine reuptake at human NET expressed in MDCK-Net6 cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
AID619831Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
AID1377752Effective permeability of the compound at 25 ug/ml by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID357473Inhibition of [3H]NE uptake at human NET L169T mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID172542In vivo noradrenergic responsiveness in the rat pineal gland at 10 mg/kg (ip) (chronic treatment)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1207635Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1637714Permeability of the compound at 100 ug/ml measured after 10 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID238667Inhibitory constant against reuptake of [3H]5-HT at serotonin transporter of rat midbrain cortex2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants.
AID1135985Mydriatic effect in iv dosed NMRI albino mouse assessed as concentration required to increase pupil diameter by 200%1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID357488Inhibition of [3H]NE uptake at human NET D378A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID339421Antidepressant activity in mouse assessed as decrease in immobility time at 16 mg/kg, ip2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID1377751Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID339422Antinociceptive activity in CD1 mouse assessed as reduction in p-phenylquinone-induced abdominal constricitions at 10 mg/kg, sc after 60 mins relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID1063770Displacement of [3H]Nisoxetine from norepinephrine transporter (unknown origin)2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.
AID91721Inhibition of binding of [3H]imipramine to imipramine receptor in rat brain1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1900247Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
AID110190Ability to antagonise tetrabenazine (TBZ)-induced depression measured in mice for ptosis by subcutaneous administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID196062Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1357285Dissociation constant, pKa of the compound2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID185584Percent inhibitory activity caused by norepinephrine after ip injection of 10 mg/kg administered once a day for 21 days (chronic treatment)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID351887Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID1230204Permeability of the compound by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID696005Permeability of the compound after 4 hrs by PAMPA assay2012European journal of medicinal chemistry, Dec, Volume: 58Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
AID22432Volume of distribution in the plasma fluid was determined1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID550800Ratio of drug level in whole brain to plasma of mouse at 30 mg/kg, po after 120 mins2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1167550Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64527Ki uptake/Ki binding ratio was determined1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.
AID357496Inhibition of [3H]NE uptake at human NET L543P mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID327170Binding affinity to human serum albumin by PAMPA method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID1626222Displacement of [3H]nisoxetine from human NET expressed in HEK293 cells at 10 uM measured after 30 mins2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1623078Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID357490Inhibition of [3H]NE uptake at human NET A384P mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID427196Membrane permeability by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID224550Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID537545Displacement of [3H]N-R-methylhistamine from human H3 receptor isolated from C6 cells2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID751640Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells after 3 hrs2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID65349Ability to inhibit reuptake of dopamine ([3H]DA) at dopamine transporter of rat striatum2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and pharmacological evaluation of (Z)-9-(heteroarylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes: thiophene analogues as potent norepinephrine transporter inhibitors.
AID357492Inhibition of [3H]NE uptake at human NET K463N mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID357493Inhibition of [3H]NE uptake at human NET L469A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID180130Inhibition of uptake of Dopamine in rat brain slices1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID469403Permeability across PAMPA membrane 2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID357476Inhibition of [3H]NE uptake at human NET G177N mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1173449Effective permeability of the compound by PAMPA assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID516915Increase of normetanephrine level in NMRI mouse cortex at 10 mg/kg, ip after 1 hr microwave irradiation2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Rigid analogues of the α2-adrenergic blocker atipamezole: small changes, big consequences.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID682275TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Desipramine: 500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID238634Inhibitory constant against reuptake of [3H]NE at norepinephrine transporter of rat parietal-occipital cortex2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants.
AID284828Binding affinity at NET2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET.
AID28921Partition coefficient (logP) (hexadecane)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID289404Inhibition of [3H]dopamine uptake in human DAT P387A mutant transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID289406Inhibition of [3H]dopamine uptake in human DAT F472L mutant transfected HEK293 cells2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID357494Inhibition of [3H]NE uptake at human NET L469F mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID678806TP_TRANSPORTER: inhibition of TEA uptake in Octn1-HRPE cells2000Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID114139Inhibition of tetrabenazine ptosis in mice following i.p. administration.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Novel tetracyclic spiropiperidines. 3. 1-arylspiro[indoline-3,4'-piperidine]s as potential antidepressants.
AID620399Permeability of the compound by PAMPA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427197Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID23971logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID185583Percent inhibitory activity caused by norepinephrine after 1 i.p. injection of 10 mg/kg administered (acute treatment)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID183050Compound was tested in vitro for beta -adrenergic sensitivity and administered to rats at 10 mg/kg, perorally, twice daily for 10 days.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
(+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 1. Synthesis and evaluation of (+/-)-4,5-dihydro-2,3-dimethyl-4-phenyl-3H-1,3-benzodiazepine and analogues as potential antidepressant agents.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID351894Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID624696Mechanism based inhibition of rat cytochrome P450 CYP2C11 measured by 2-alpha and 16-alpha hydroxylation of testosterone2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID48900Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 1 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID1135979Inhibition of noradrenaline transporter in NMRI albino mouse brain assessed as [3H]NA accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID357475Inhibition of [3H]NE uptake at human NET D175A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID351891Cytotoxicity against C57BL/6J mouse splenocytes after 72 hrs by alamar blue assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1636479Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 139.9 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1480943Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID159538Tested for in vitro reuptake inhibition of [3H]dopamine in pig striatal synaptosomes.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
3-[(2-ethoxyphenoxy)methyl]piperidine derivatives. Synthesis and antidepressant activity.
AID578393Antidepressant activity in mouse assessed as immobility at 100 mg/kg, po measured after 30 mins2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID132407Inhibition of tetrabenazine-induced ptosis in mice following i.p. administration.1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 6. Synthesis, 13C NMR, and biological evaluation of cis- and trans-4-amino-3'-arylspiro[cyclohexane-1,1'(3'H)-isobenzofuran] derivatives.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID178311Antidepressant activity by tetrabenazine ptosis prevention in mice after oral administration1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Novel tetracyclic spiropiperidines. 3. 1-arylspiro[indoline-3,4'-piperidine]s as potential antidepressants.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID351897Chemosensitizing activity after 72 hrs against chloroquine-resistant Plasmodium falciparum Dd2 infected human erythrocytes as IC50 ratio chloroquine +/- 500 nM by SYBR green assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID1636268Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID537543Displacement of [3H]nisoxetine from rat NET in rat cerebral cortex2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID1207212Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID127795In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID681146TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1056992Permeability of the compound by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID351893Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by SYBR green assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID357498Inhibition of [3H]NE uptake at human NET D547A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID452389Inhibition of norepinephrine reuptake at NET2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.
AID327169Apparent permeability across parallel artificial membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.
AID64525In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography.
AID183728Inhibitory activity of compound against ability of NE to enhance the inhibition produced by GABA after ip injection of 10 mg/kg administered once a day for 21 days (chronic treatment)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID132965In vivo antagonism of reserpine-induced hypothermia in the mice1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID112337Evaluated for antidepressant activity by its ability to inhibit tetrabenazine-induced (TBZ) ptosis in mice1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
7-(Aminoacyl) and 7-(aminoalkyl) derivatives of 1,2,6,7-tetrahydroindolo[1,7-ab][1,5]benzodiazepines as potential antidepressant agents.
AID1511119Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID36031Compound was tested for its inhibitory activity against Alpha-1 adrenergic receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID357485Inhibition of [3H]NE uptake at human NET D298A mutant expressed in african green monkey COS1 cells after 48 hrs2007The Journal of biological chemistry, Jun-15, Volume: 282, Issue:24
chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID773432Displacement of [3H]Nisoxetine from human recombinant NET over-expressed in dog MDCK cells2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1705959Effective permeability of compound at 100 ug/ml incubated for 20 hrs by PAMPA-BBB assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID180129Inhibition of uptake of 5-HT in rat brain slices1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1628449Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as chloroquine-coumarin probe accumulation at 10 uM after 10 hrs by Hoechst 33342 staining based flow cytometry (Rvb = 35.57 +/- 3.84%)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID351896Chemosensitizing activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as IC50 ratio chloroquine +/- 500nM by SYBR green assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID48902Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 3 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1799301Radioligand Binding Assay (Ki) from Article 10.1016/j.bmc.2009.09.023: \\Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.\\2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346943Human SERT (Monoamine transporter subfamily)1997The Journal of pharmacology and experimental therapeutics, Dec, Volume: 283, Issue:3
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.
AID1346535Mouse Kir3.4 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346955Rat SERT (Monoamine transporter subfamily)2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2005Molecular pharmacology, Nov, Volume: 68, Issue:5
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2016Clinical pharmacology and therapeutics, Nov, Volume: 100, Issue:5
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
AID1346971Human NET (Monoamine transporter subfamily)2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,498)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902979 (54.18)18.7374
1990's1296 (23.57)18.2507
2000's746 (13.57)29.6817
2010's423 (7.69)24.3611
2020's54 (0.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.65 (24.57)
Research Supply Index8.74 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index137.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials487 (8.43%)5.53%
Reviews182 (3.15%)6.00%
Case Studies234 (4.05%)4.05%
Observational0 (0.00%)0.25%
Other4,872 (84.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (38)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide. [NCT03726996]Phase 44 participants (Actual)Interventional2019-01-14Terminated(stopped due to Funding exhausted)
Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization [NCT03548454]Phase 4320 participants (Anticipated)Interventional2018-09-20Recruiting
A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate [NCT01358968]Phase 120 participants (Actual)Interventional2011-06-30Completed
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors [NCT01265550]Phase 3366 participants (Actual)Interventional2012-08-13Completed
Efficacy of Antidepressants in Chronic Back Pain [NCT00964886]Phase 2142 participants (Actual)Interventional2010-01-31Completed
A Two-Way Single Dose Crossover Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets [NCT00913809]Phase 136 participants (Actual)Interventional1987-12-31Completed
Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma [NCT01899326]10 participants (Actual)Interventional2013-09-30Terminated(stopped due to The study was stopped during the interim analysis due to low accrual after the widespread use of plerixafor for multiple myeloma in the United States.)
Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome [NCT00990691]Phase 236 participants (Actual)Interventional2009-02-17Completed
Naltrexone & SSRI in Alcoholics With Depression/PTSD [NCT00338962]Phase 388 participants (Actual)Interventional2001-10-31Completed
A Two-Way Crossover Bioequivalency Study Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets [NCT00914004]Phase 136 participants (Actual)InterventionalCompleted
Randomized, 2-way Crossover Bioavailability Study of Desipramine Hydrochloride 50 mg Tablets [NCT00913237]Phase 136 participants (Actual)Interventional1987-07-31Completed
Bioavailability of Desipramine Hydrochloride Tablets [NCT00913822]Phase 136 participants (Actual)Interventional1987-12-31Completed
Do Antidepressants Reverse the Effects of Early Life Stress on the Brain and Thrombovascular System and Improve Psychological, Neuroendocrine, and Platelet Function: A Study of Men and Women With Childhood Abuse. [NCT00166114]Phase 440 participants (Actual)Interventional2002-02-28Completed
Multicenter Trial of Functional Bowel Disorders [NCT00006157]Phase 3300 participants Interventional1996-07-31Completed
A PHASE I, SINGLE-CENTER, OPEN-LABEL, CROSSOVER STUDY OF THE EFFECT OF AVANAFIL ON THE PHARMACOKINETICS OF OMEPRAZOLE, DESIPRAMINE AND ROSIGLITAZONE IN HEALTHY MALE SUBJECTS [NCT01415128]Phase 160 participants (Actual)Interventional2010-04-30Completed
An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine [NCT00500721]Phase 122 participants (Anticipated)Interventional2007-06-30Completed
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects [NCT01478568]Phase 128 participants (Actual)Interventional2008-10-31Completed
[NCT00265291]Phase 2700 participants (Actual)Interventional1999-11-30Completed
Psychopharmacology of Biogenic Amines in Depression [NCT00320632]Phase 443 participants Interventional1990-08-31Completed
Effect of Tricyclic Antidepressant Agents on Gastric Accommodation and Emptying [NCT00220844]10 participants (Actual)Interventional2005-09-30Terminated(stopped due to Futility; study coordinator left and were unable to continue data collection; missing data)
A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00329147]Phase 320 participants (Anticipated)Interventional2006-05-31Completed
New Approaches to Cocaine Abuse Medications (A) [NCT00000271]Phase 2111 participants (Actual)Interventional1995-01-31Completed
Biological Aspects of Depression and Antidepressant Drugs [NCT00018733]0 participants Interventional1996-09-30Completed
Efficacy of Antidepressants in Chronic Back Pain [NCT00018200]Phase 2130 participants (Actual)Interventional1999-04-30Completed
Vulvar Vestibulitis Trial: Desipramine-Lidocaine [NCT00276068]128 participants (Anticipated)Interventional2002-08-31Completed
A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00366652]Phase 320 participants (Anticipated)Interventional2006-09-30Completed
Methamphetamine Abuse Pharmacology in Patients With AIDS [NCT00000321]Phase 40 participants Interventional1996-10-31Completed
[NCT00000376]0 participants Interventional1996-03-31Completed
[NCT00004390]Phase 3120 participants Interventional1995-02-28Completed
Pharmacokinetics of 50 mg Desipramine Daily, Given Orally Over 7 Days With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomize [NCT02273466]Phase 124 participants (Actual)Interventional2002-02-28Completed
IV Cocaine Abuse: A Laboratory Model [NCT00000212]Phase 20 participants Interventional1987-07-31Completed
Evaluation of a Desipramine Ceiling in Cocaine Abuse [NCT00000245]Phase 20 participants Interventional1994-05-31Completed
The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects [NCT02428478]Phase 217 participants (Actual)Interventional2015-03-31Completed
The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B [NCT02436031]Phase 216 participants (Actual)Interventional2015-04-30Completed
Alcoholism and Schizophrenia: A Translational Approach to Treatment [NCT01411085]Phase 212 participants (Actual)Interventional2011-12-31Completed
A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors [NCT01719861]Phase 26 participants (Actual)Interventional2012-10-31Terminated(stopped due to Lack of efficacy)
The Modulation of Cerebral Pain Responses Using Desipramine in the Treatment of Irritable Bowel Syndrome (IBS) [NCT00880594]70 participants (Actual)Interventional2009-02-28Completed
Biological Predictors of Response to Antidepressants [NCT00456014]37 participants (Actual)Interventional2006-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00166114 (1) [back to overview]Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8
NCT00338962 (4) [back to overview]Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)
NCT00338962 (4) [back to overview]Mean Number of Side Effects
NCT00338962 (4) [back to overview]Hamilton Depression Rating Scale (HAM-D)
NCT00338962 (4) [back to overview]Clinician-Administered PTSD Scale (CAPS)
NCT00456014 (3) [back to overview]Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase
NCT00456014 (3) [back to overview]Remission of Depressive Symptoms - Tricyclic Phase
NCT00456014 (3) [back to overview]Remission of Depressive Symptoms
NCT00964886 (2) [back to overview]Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity
NCT00964886 (2) [back to overview]Roland and Morris Disability Questionnaire
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Achalasia
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Diarrhea
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Aperistalsis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Belching Disorders
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Candida Esophagitis.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Chronic Idiopathic Nausea
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Cyclic Vomiting Syndrome
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Distal Esophageal Spasm
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Eosinophilic Esophagitis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Esophageal Ulceration.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Bloating
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Dysphagia
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Gallbladder Disorder
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Heartburn
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Functional Vomiting
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Gastric Outlet Obstruction
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Globus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Hypertensive Peristalsis
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Ineffective Esophageal Motility
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Irritable Bowel Syndrome
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Jackhammer Esophagus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Nutcracker Esophagus
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Rapid Contraction
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Reflux Esophagus.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Unspecified Functional Bowel Disorder
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Weak Peristalsis I
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Weak Peristalsis II
NCT01265550 (54) [back to overview]Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months
NCT01265550 (54) [back to overview]Number of Successful Participants With Anxiety and/or Depression.
NCT01265550 (54) [back to overview]Number of Successful Participants With Belching Disorders
NCT01265550 (54) [back to overview]Number of Successful Participants With Chronic Idiopathic Nausea
NCT01265550 (54) [back to overview]Number of Successful Participants With Cyclic Vomiting Syndrome
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Bloating
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Diarrhea
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Dysphagia
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Gallbladder Disorder
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Heartburn
NCT01265550 (54) [back to overview]Number of Successful Participants With Functional Vomiting
NCT01265550 (54) [back to overview]Number of Successful Participants With Globus
NCT01265550 (54) [back to overview]Number of Successful Participants With Irritable Bowel Syndrome
NCT01265550 (54) [back to overview]Number of Successful Participants With Unspecified Functional Bowel Disorder
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.
NCT01265550 (54) [back to overview]Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.
NCT01265550 (54) [back to overview]Number of Enrolled Participants With Anxiety and/or Depression
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of Desipramine: the Maximum Concentration of Desipramine in the Plasma (Cmax)
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of Desipramine [AUC(0-tlast)]
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax)
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of LY2603618 [AUC(0-tlast)]
NCT01358968 (7) [back to overview]Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]
NCT01358968 (7) [back to overview]Number of Participants With a Tumor Response
NCT01411085 (1) [back to overview]Timeline Followback Assessing Number of Drinks Per Week
NCT01719861 (5) [back to overview]Desipramine Maximum Dose
NCT01719861 (5) [back to overview]Median Overall Survival (OS)
NCT01719861 (5) [back to overview]Median Serum Desipramine Levels During Treatment
NCT01719861 (5) [back to overview]Overall Response Rate (ORR)
NCT01719861 (5) [back to overview]Progression-free Survival (PFS), Median
NCT01899326 (5) [back to overview]Incidence of Adverse Events
NCT01899326 (5) [back to overview]Median Time to Neutrophil Engraftment
NCT01899326 (5) [back to overview]Median Time to Platelet Engraftment
NCT01899326 (5) [back to overview]Success Rate of Stem Cell Mobilization (SCM) in Participants Who Completed Filgrastim and Desipramine Therapy
NCT01899326 (5) [back to overview]Median Number of Days of Apheresis
NCT02428478 (2) [back to overview]Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility
NCT02428478 (2) [back to overview]Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity
NCT02436031 (3) [back to overview]Number of Apnoea-Hypopnea Index (AHI) Events During Non-Random Eye Movement (NREM) Sleep
NCT02436031 (3) [back to overview]Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility
NCT02436031 (3) [back to overview]Genioglossus Muscle Responsiveness to Progressively Greater Epiglottic Pressure Swings
NCT03726996 (2) [back to overview]Number of Participants With Change in Q-T Interval on ECG
NCT03726996 (2) [back to overview]Number of Participants With Abnormal Transaminase Values

Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8

"Number of subjects that showed no response, partial response, and response based on scores from baseline and week 8.~The 21-item HDRS measures depression severity. The scoring is sum the total of all 21 items to arrive at the total score, with a range of 0 to 60, where higher scores indicated greater severity. Nine items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Eleven items are scored from 0 - 2 (0 = absent and 2 = severe). The last item is scored on a 4-point scale of 0-3 (0 = absent and 3 = severe). The HDRS at week 8 was compared to the baseline HDRS and each participant's response was calculated using the below table:~No Response = < 25% change in Depression Rating Scale Score Partial Responder = < 50% to >25% change in Depression Rating Scale Score Responder = 50% or greater change in Depression Rating Scale Score" (NCT00166114)
Timeframe: Baseline, Week 8

,
Interventionparticipants (Number)
ResponseNo or Partial Response
Desipramine94
Escitalopram52

[back to top]

Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)

The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48. (NCT00338962)
Timeframe: beginning of treatment (week 1), and end of treatment (13 weeks)

,,,
Interventionunits on a scale (Mean)
Week 1Week 13
Desipramine and Naltrexone18.5004.296
Desipramine and Placebo21.4587.489
Paroxetine and Naltrexone21.27310.013
Paroxetine and Placebo20.7009.690

[back to top]

Mean Number of Side Effects

Differences in mean number of side effects reported for each group. Side effects and common adverse symptoms were evaluated by the research staff weekly, using a modified version of the ystematic Assessment for Treatment Emergent Events. The symptoms that are known to be associated with treatment with desipramine, paroxetine, and naltrexone were specifically screened or on a weekly basis. The symptoms were then clustered into the following categories: gastrointestinal, emotional, cold and flu symptoms, skin, sexual, neurological, and cardiac. (NCT00338962)
Timeframe: 12 weeks

,,,
Interventionside effects (Mean)
Gastrointestinal symptomsEmotional SymptomsNeurological SymptomsCold SymptomsSkin SymptomsSexual SymptomsCardiac Symptoms
Desipramine and Naltrexone3.0523.7274.2011.891.591.737.389
Desipramine and Placebo3.6535.2484.5662.2531.057.736.356
Paroxetine and Naltrexone3.6514.8746.2122.1821.002.877.416
Paroxetine and Placebo2.6883.9635.0782.393.859.932.474

[back to top]

Hamilton Depression Rating Scale (HAM-D)

The HAM-D ranges from 0 (Normal) to >23 (Very Severe Depression) (NCT00338962)
Timeframe: beginning of treatment (week 1), and end of treatment (13 weeks)

,,,
Interventionunits on a scale (Mean)
Beginning of TreatmentEnd of Treatment
Desipramine and Naltrexone11.1958.563
Desipramine and Placebo13.1678.943
Paroxetine and Naltrexone13.2739.328
Paroxetine and Placebo10.9508.238

[back to top]

Clinician-Administered PTSD Scale (CAPS)

"The CAPS is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to:~Make current (past month) diagnosis of PTSD Make lifetime diagnosis of PTSD Assess PTSD symptoms over the past week Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD >80=Extreme PTSD" (NCT00338962)
Timeframe: beginning of treatment (week 1), and end of treatment (13 weeks)

,,,
Interventionunits on a scale (Mean)
Beginning of TreatmentEnd of Treatment
Desipramine and Naltrexone62.50026.751
Desipramine and Placebo77.83341.392
Paroxetine and Naltrexone73.5440.024
Paroxetine and Placebo69.81036.591

[back to top]

Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase

Mean % improvement from baseline to end of treatment trial using the 24-item Hamilton Depression Rating Scale. Percent improvement of depressive symptoms was calculated for the 28 completers of the SSRI phase. The higher the score on the 24-item HDRS, the greater the depression severity. Minimum score on the scale is 0, and maximum score is 74. Subscales are not used for this analysis. (NCT00456014)
Timeframe: Measured at Week 8

Intervention% improvement in depression symptoms (Mean)
Escitalopram ImprovementSertraline Improvement
1 - SSRI45.4630.01

[back to top]

Remission of Depressive Symptoms - Tricyclic Phase

Participants who did not achieve remission during the SSRI phase advanced to the tricyclic phase of the study. Participants were treated with either desipramine or nortriptyline. Seven participants started the tricyclic phase. Four completed the tricyclic phase. The completers (n=4) were analyzed for remission status. (NCT00456014)
Timeframe: Measured over 8 weeks

Interventionparticipants (Number)
Number Achieving RemissionNumbering Failing to Remit
Tricyclic Group13

[back to top]

Remission of Depressive Symptoms

Remission in this study is defined as both a ≥50% decrease in the 24-item Hamilton Depression Rating Scale (HDRS) Score and a final 24-item HDRS score <10. Remission of depressive symptoms was calculated for the 28 completers of the SSRI phase. (NCT00456014)
Timeframe: Measured at Week 8

Interventionparticipants (Number)
Participants achieving remissionParticipants failing to achieve remission
1 - SSRI1414

[back to top]

Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity

"The DDS is self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor words which serve as anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline or last observation carried forward, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)

Interventionunits on a scale (Mean)
Arm 1 + Arm 38.3
Arm 2 + Arm 48.1
Arm 2 + Arm 38.0
Arm 1 + Arm 48.4

[back to top]

Roland and Morris Disability Questionnaire

"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)

InterventionUnits on a scale. (Mean)
Arm 1 + Arm 38.7
Arm 2 + Arm 48.9
Arm 2 + Arm 38.7
Arm 1 + Arm 48.9

[back to top]

Number of Enrolled Participants With Achalasia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Functional Diarrhea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

[back to top]

Number of Enrolled Participants With Aperistalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Belching Disorders

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled130

[back to top]

Number of Enrolled Participants With Candida Esophagitis.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Chronic Idiopathic Nausea

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled51

[back to top]

Number of Enrolled Participants With Cyclic Vomiting Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled86

[back to top]

Number of Enrolled Participants With Distal Esophageal Spasm

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Eosinophilic Esophagitis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled16

[back to top]

Number of Enrolled Participants With Esophageal Ulceration.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Functional Bloating

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

[back to top]

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled13

[back to top]

Number of Enrolled Participants With Functional Dysphagia

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled7

[back to top]

Number of Enrolled Participants With Functional Gallbladder Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

[back to top]

Number of Enrolled Participants With Functional Heartburn

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled221

[back to top]

Number of Enrolled Participants With Functional Vomiting

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled32

[back to top]

Number of Enrolled Participants With Gastric Outlet Obstruction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Globus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Hypertensive Peristalsis

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled3

[back to top]

Number of Enrolled Participants With Ineffective Esophageal Motility

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled1

[back to top]

Number of Enrolled Participants With Irritable Bowel Syndrome

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled152

[back to top]

Number of Enrolled Participants With Jackhammer Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled8

[back to top]

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled0

[back to top]

Number of Enrolled Participants With Nutcracker Esophagus

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Enrolled Participants With Rapid Contraction

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled2

[back to top]

Number of Enrolled Participants With Reflux Esophagus.

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled4

[back to top]

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled56

[back to top]

Number of Enrolled Participants With Weak Peristalsis I

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled10

[back to top]

Number of Enrolled Participants With Weak Peristalsis II

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled9

[back to top] [back to top]

Number of Successful Participants With Anxiety and/or Depression.

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Belching Disorders

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group12
Placebo Medical Treatment Group2

[back to top]

Number of Successful Participants With Chronic Idiopathic Nausea

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group3
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Cyclic Vomiting Syndrome

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group7
Placebo Medical Treatment Group1

[back to top]

Number of Successful Participants With Functional Bloating

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Diarrhea

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Dysphagia

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Gallbladder Disorder

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Functional Heartburn

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group7
Surgical Treatment Group14
Placebo Medical Treatment Group3

[back to top]

Number of Successful Participants With Functional Vomiting

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group1
Surgical Treatment Group1
Placebo Medical Treatment Group1

[back to top]

Number of Successful Participants With Globus

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group0
Surgical Treatment Group0
Placebo Medical Treatment Group0

[back to top]

Number of Successful Participants With Irritable Bowel Syndrome

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group3
Surgical Treatment Group10
Placebo Medical Treatment Group3

[back to top]

Number of Successful Participants With Unspecified Functional Bowel Disorder

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Medical Treatment Group2
Surgical Treatment Group5
Placebo Medical Treatment Group0

[back to top]

Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

[back to top]

Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group15

[back to top]

Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group18

[back to top]

Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.

(NCT01265550)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgical Treatment Group14

[back to top]

Number of Enrolled Participants With Anxiety and/or Depression

(NCT01265550)
Timeframe: Screening

InterventionParticipants (Count of Participants)
All Enrolled125

[back to top]

Plasma Pharmacokinetics of Desipramine: the Maximum Concentration of Desipramine in the Plasma (Cmax)

(NCT01358968)
Timeframe: Periods 1 and 2: Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose

Interventionnanograms/milliliter (ng/mL) (Geometric Mean)
Period 1Period 2
Desipramine21.222.8

[back to top]

Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of Desipramine [AUC(0-tlast)]

(NCT01358968)
Timeframe: Periods 1 and 2: Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose

Interventionnanogram*hour/milliliter (ng*h/mL) (Geometric Mean)
Period 1Period 2
Desipramine619653

[back to top]

Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]

(NCT01358968)
Timeframe: Periods 1 and 2: Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose

Interventionnanograms*hour/milliliter (ng*h/mL) (Geometric Mean)
Period 1Period 2
Desipramine655687

[back to top]

Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax)

(NCT01358968)
Timeframe: Period 2 only: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours post dose

Interventionnanograms/milliliter (ng/mL) (Geometric Mean)
LY26036185950

[back to top]

Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of LY2603618 [AUC(0-tlast)]

(NCT01358968)
Timeframe: Period 2 only: Predose 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours post dose

Interventionnanograms*hour/milliliter (ng*h/mL) (Geometric Mean)
LY260361853000

[back to top]

Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]

(NCT01358968)
Timeframe: Period 2 only: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours post dose

Interventionnanograms*hour/milliliter (ng*h/mL) (Geometric Mean)
LY260361853700

[back to top]

Number of Participants With a Tumor Response

Tumor response is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (Version 1.1). CR is the disappearance of all target and non-target lesions and PR is a ≥30% decrease in sum of longest diameter of target lesions. Number of participants with a tumor response is the total number of participants with CR or PR. (NCT01358968)
Timeframe: Baseline to study completion up to 11 cycles of 21-day cycles

InterventionParticipants (Count of Participants)
LY2603618 + Gemcitabine (Continued Access)1
LY2603618 + Pemetrexed (Continued Access)0

[back to top]

Timeline Followback Assessing Number of Drinks Per Week

Alcohol/other substance use (including tobacco) will be assessed primarily by weekly self-report using the Timeline Followback (TLFB) method enhanced by procedures to strengthen the reliability and validity of this measure. It involves asking participants to retrospectively estimate their alcohol and other substance use. (NCT01411085)
Timeframe: Weekly for 14 weeks, using data from last 8 weeks

InterventionDrinks per week (Mean)
Risperidone + Desipramine35.9

[back to top]

Desipramine Maximum Dose

Assessed as the median per patient maximum dose (MD) using intra-patient dose escalation, and reported as the highest dose of desipramine administered continuously for 1 week or greater. (NCT01719861)
Timeframe: Up to 6 weeks

Interventionmg daily (Median)
Desipramine HCl75

[back to top]

Median Overall Survival (OS)

Median overall survival was defined as time from enrollment to death from any cause calculated using the Kaplan-Meier method. (NCT01719861)
Timeframe: From start of enrollment until death, no limit

InterventionMonths (Median)
Desipramine HCl2.7

[back to top]

Median Serum Desipramine Levels During Treatment

"Median serum desipramine levels during treatment is reported as the median of the maximum steady state serum concentration observed in all patients.~Therapeutic concentration of desipramine is 100 to 300 ng/mL, and toxic concentration is > 300 ng/mL." (NCT01719861)
Timeframe: Up to 6 weeks

Interventionng/mL (Median)
Desipramine HCl132

[back to top]

Overall Response Rate (ORR)

Overall response rate (ORR) was assessed as the number of patients who achieve either a partial (PR) or complete response (CR) measured by CT scans and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria, divided by the total number of patients treated on the study. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion. (NCT01719861)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Desipramine HCl 25 mg0

[back to top]

Progression-free Survival (PFS), Median

Median PFS was defined as the time from randomization to disease progression (or death if the patient died before progression) calculated using the Kaplan-Meier method. (NCT01719861)
Timeframe: Up to 5 years from enrollment to radiographic progression or drug discontinuation

InterventionMonths (Median)
Desipramine HCl1.2

[back to top]

Incidence of Adverse Events

Incidence of adverse events up to 1 week following completion of study treatment. Adverse events were graded using Version 4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). (NCT01899326)
Timeframe: Up to 1 week following completion of study treatment, up to 15 days

InterventionAdverse Events (Number)
Treatment (Desipramine, Filgrastim)9

[back to top]

Median Time to Neutrophil Engraftment

Median time (number of days) to neutrophil engraftment was determined as first of three consecutive days with absolute neutrophil count (ANC) > 500/ul or first day with ANC > 1000/ul in the absence of growth factor support. (NCT01899326)
Timeframe: Up to 1 week following completion of study treatment, up to 15 days

Interventionnumber of days (Median)
Treatment (Desipramine, Filgrastim)12

[back to top]

Median Time to Platelet Engraftment

Median time (number of days) to platelet engraftment was determined as first of three consecutive days with platelets > 20,000/ul without transfusion. (NCT01899326)
Timeframe: Up to 1 week following completion of study treatment, up to 15 days

Interventionnumber of days (Median)
Treatment (Desipramine, Filgrastim)13.5

[back to top]

Success Rate of Stem Cell Mobilization (SCM) in Participants Who Completed Filgrastim and Desipramine Therapy

Success rate was assessed as the number of participants with Multiple Myeloma (MM) who were first time mobilizers or unexposed to alkylating agents who completed the full course of filgrastim and desipramine and achieved the target collection of >=5 x 10^6 CD34+ cells/kg. (NCT01899326)
Timeframe: Day 5

InterventionParticipants (Count of Participants)
Treatment (Desipramine, Filgrastim)6

[back to top]

Median Number of Days of Apheresis

Median number of days of apheresis required to collect >=5 x 10^6 CD34+ cells/kg. Standard descriptive statistics were used to summarize the data. (NCT01899326)
Timeframe: Up to 1 week following completion of study treatment, up to 15 days

InterventionDays (Median)
Treatment (Desipramine, Filgrastim)1.5

[back to top]

Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility

Participants were connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which provided a wide range of pressures between 20 and -20 cm H2O in order to modify upper airway pressure. Following a baseline recording period of 5 minutes, the CPAP level was reduced to varying suboptimal pressures. Change in Pcrit was used to determine the collapsibility of the upper airway under both passive and active conditions, and is expressed as Passive Pcrit: ventilation at a nasal pressure of 0 cm H2O when pharyngeal muscles are passive; Active Pcrit: ventilation at a nasal pressure of 0 cm H2O when pharyngeal muscles are active. Improved=more negative Pcrit. (NCT02428478)
Timeframe: 1 night

,
Interventioncm H2O (Median)
Passive PcritActive Pcrit
Desipramine-10.0-14.9
Placebo-8.1-10.5

[back to top]

Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity

Electromyography (EMG) was used to analyze genioglossus (GG) [EMG GG] muscle movement. EMG GG activity was recorded via standard needle electrodes inserted into the genioglossus (tongue) muscle. Activity of EMG GG was measured during wakefulness and sleep as % of maximum activation obtained pushing the tongue against closed teeth during wakefulness (GG%max). Sleep values were then expressed as %wakefulness value for tonic and phasic EMG GG activity. Tonic activity was defined as the lowest EMG GG value during expiration, phasic activity was calculated as the peak value during inspiration minus the tonic value. (NCT02428478)
Timeframe: 1 night

,
Interventionpercent wakefulness (Median)
TonicPhasic
Desipramine9684
Placebo7593

[back to top]

Number of Apnoea-Hypopnea Index (AHI) Events During Non-Random Eye Movement (NREM) Sleep

The AHI is the number of apneas (pauses in breathing) or hypopneas (shallow breathing) recorded during the study per hour of sleep. Data for the calculation of the AHI was collected while the participant was in NREM sleep in the supine position and off CPAP (breathing spontaneously). (NCT02436031)
Timeframe: 1 night

Interventionevents per hour (Median)
Desipramine34.3
Placebo42.0

[back to top]

Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility

Participants were connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which provided a wide range of pressures between 20 and -20 cm H2O in order to modify upper airway pressure. Following a baseline recording period of 5 minutes, the CPAP level was reduced to varying suboptimal pressures. Change in Pcrit was used to determine the collapsibility of the upper airway under both passive and active conditions, and is expressed as Passive Pcrit: ventilation at a nasal pressure of 0 cm H2O when pharyngeal muscles are passive; Active Pcrit: ventilation at a nasal pressure of 0 cm H2O when pharyngeal muscles are active. Improved=more negative Pcrit. (NCT02436031)
Timeframe: 1 night

,
Interventioncm H2O (Median)
Active PcritPassive Pcrit
Desipramine-5.2-2.2
Placebo-1.9-0.7

[back to top]

Genioglossus Muscle Responsiveness to Progressively Greater Epiglottic Pressure Swings

Electromyography (EMG) was used to analyze genioglossus (GG) [EMG GG] muscle activity. EMG GG activity was recorded via standard needle electrodes inserted into the genioglossus muscle (tongue). Activity of EMG GG was measured during wakefulness and sleep as % of maximum activation obtained pushing the tongue against closed teeth during wakefulness (GG%max). Participants were connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which provided a wide range of pressures between 20 and -20 cm H2O in order to modify upper airway pressure and measure change in EMG GG as a function of epiglottic pressure (muscle responsiveness) (%max/cmH2O). (NCT02436031)
Timeframe: 1 night

Intervention%max/cmH2O (Median)
Desipramine-0.24
Placebo-0.25

[back to top]

Number of Participants With Change in Q-T Interval on ECG

Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug. The Q-T interval is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation. Participants with a prolonged Q-T interval at any timepoint is reported. (NCT03726996)
Timeframe: Baseline, 3, 6, 9, and 12 months

InterventionParticipants (Count of Participants)
Children With INAD1

[back to top]

Number of Participants With Abnormal Transaminase Values

Transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST). Participants with abnormal transaminase values at any timepoint is reported. (NCT03726996)
Timeframe: Baseline, 3, 6, 9, and 12 months

InterventionParticipants (Count of Participants)
Children With INAD0

[back to top]